Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2022 | Nov. 03, 2022 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2022 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2022 | |
Document Fiscal Period Focus | Q1 | |
Document Transition Report | false | |
Entity File Number | 0-16211 | |
Entity Registrant Name | DENTSPLY SIRONA Inc. | |
Entity Central Index Key | 0000818479 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 39-1434669 | |
Entity Address, Address Line One | 13320 Ballantyne Corporate Place | |
Entity Address, City or Town | Charlotte | |
Entity Address, State or Province | NC | |
Entity Address, Postal Zip Code | 28277-3607 | |
City Area Code | 844 | |
Local Phone Number | 848-0137 | |
Title of 12(b) Security | Common Stock, par value $.01 per share | |
Trading Symbol | XRAY | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | No | |
Entity Interactive Data Current | No | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 214,911,886 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Income Statement [Abstract] | ||
Net sales | $ 969 | $ 1,026 |
Cost of products sold | 448 | 447 |
Gross profit | 521 | 579 |
Selling, general, and administrative expenses | 376 | 386 |
Research and development expenses | 45 | 40 |
Provisions | 3 | 3 |
Operating income | 97 | 150 |
Other income and expenses: | ||
Interest expense, net | 12 | 14 |
Other expense (income), net | (2) | (9) |
Income before income taxes | 87 | 145 |
Provision for income taxes | 18 | 33 |
Net income | 69 | 112 |
Less: Net income attributable to noncontrolling interest | 0 | 0 |
Net income attributable to Dentsply Sirona | $ 69 | $ 112 |
Net income per common share attributable to Dentsply Sirona: | ||
Basic (in dollars per share) | $ 0.32 | $ 0.51 |
Diluted (in dollars per share) | $ 0.32 | $ 0.51 |
Weighted average common shares outstanding: | ||
Basic (in shares) | 217 | 218.8 |
Diluted (in shares) | 217.8 | 219.9 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Statement of Comprehensive Income [Abstract] | ||
Net income | $ 69 | $ 112 |
Other comprehensive loss, net of tax: | ||
Foreign currency translation loss | (48) | (99) |
Net gain on derivative financial instruments | 10 | 5 |
Pension liability gain | 1 | 4 |
Net (decrease) increase in other comprehensive loss | (37) | (90) |
Total comprehensive income | 32 | 22 |
Less: Comprehensive income attributable to noncontrolling interests | 0 | 0 |
Total comprehensive income attributable to Dentsply Sirona | $ 32 | $ 22 |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Current Assets: | ||
Cash and cash equivalents | $ 374 | $ 339 |
Accounts and notes receivables-trade, net | 707 | 750 |
Inventories, net | 553 | 515 |
Prepaid expenses and other current assets | 263 | 248 |
Total Current Assets | 1,897 | 1,852 |
Property, plant, and equipment, net | 771 | 773 |
Operating lease right-of-use assets, net | 204 | 198 |
Identifiable intangible assets, net | 2,228 | 2,319 |
Goodwill | 3,944 | 3,976 |
Other noncurrent assets | 128 | 121 |
Total Assets | 9,172 | 9,239 |
Current Liabilities: | ||
Accounts payable | 277 | 262 |
Accrued liabilities | 694 | 760 |
Income taxes payable | 54 | 57 |
Notes payable and current portion of long-term debt | 347 | 182 |
Total Current Liabilities | 1,372 | 1,261 |
Long-term debt | 1,872 | 1,913 |
Operating lease liabilities | 157 | 149 |
Deferred income taxes | 389 | 391 |
Other noncurrent liabilities | 518 | 528 |
Total Liabilities | 4,308 | 4,242 |
Commitments and contingencies (Note 15) | ||
Equity: | ||
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued | 0 | 0 |
Common stock, $0.01 par value; | 3 | 3 |
Capital in excess of par value | 6,573 | 6,606 |
Retained earnings | 1,556 | 1,514 |
Accumulated other comprehensive loss | (629) | (592) |
Treasury stock, at cost, 49.0 million and 47.1 million shares at March 31, 2022 and December 31, 2021, respectively | (2,640) | (2,535) |
Total Dentsply Sirona Equity | 4,863 | 4,996 |
Noncontrolling interests | 1 | 1 |
Total Equity | 4,864 | 4,997 |
Total Liabilities and Equity | $ 9,172 | $ 9,239 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares | Mar. 31, 2022 | Dec. 31, 2021 |
Equity: | ||
Preferred stock, par value (in dollars per share) | $ 1 | $ 1 |
Preferred stock, shares authorized (in shares) | 250,000 | 250,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 400,000,000 | 400,000,000 |
Common stock, shares issued (in shares) | 264,500,000 | 264,500,000 |
Common stock, shares outstanding (in shares) | 215,500,000 | 217,400,000 |
Treasury stock, shares (in shares) | 49,000,000 | 47,100,000 |
CONSOLIDATED STATEMENTS OF CHAN
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions | Total | Total Dentsply Sirona Equity | Common Stock | Capital in Excess of Par Value | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Noncontrolling Interests |
Beginning Balance at Dec. 31, 2020 | $ 4,935 | $ 4,932 | $ 3 | $ 6,604 | $ 1,198 | $ (464) | $ (2,409) | $ 3 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 112 | 112 | 112 | |||||
Other comprehensive loss | (90) | (90) | (90) | |||||
Exercise of stock options | 33 | 33 | 11 | 22 | ||||
Stock based compensation expense | 13 | 13 | 13 | |||||
Funding of employee stock purchase plan | 3 | 3 | 1 | 2 | ||||
Treasury shares purchased | (90) | (90) | 0 | (90) | ||||
Restricted stock unit distributions | (4) | (4) | (11) | 7 | ||||
Cash dividends | (22) | (22) | (22) | |||||
Ending Balance at Mar. 31, 2021 | 4,890 | 4,887 | 3 | 6,618 | 1,288 | (554) | (2,468) | 3 |
Beginning Balance at Dec. 31, 2021 | 4,997 | 4,996 | 3 | 6,606 | 1,514 | (592) | (2,535) | 1 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | ||||||||
Net income | 69 | 69 | 69 | |||||
Other comprehensive loss | (37) | (37) | (37) | |||||
Exercise of stock options | 5 | 5 | 1 | 4 | ||||
Stock based compensation expense | 11 | 11 | 11 | |||||
Funding of employee stock purchase plan | 2 | 2 | 1 | 1 | ||||
Accelerated share repurchase | (150) | (150) | (30) | (120) | ||||
Restricted stock unit distributions | (6) | (6) | (16) | 10 | ||||
Cash dividends | (27) | (27) | (27) | |||||
Ending Balance at Mar. 31, 2022 | $ 4,864 | $ 4,863 | $ 3 | $ 6,573 | $ 1,556 | $ (629) | $ (2,640) | $ 1 |
CONSOLIDATED STATEMENTS OF CH_2
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2020 | |
Statement of Stockholders' Equity [Abstract] | ||
Dividends declared per common share (in dollars per share) | $ 0.125 | $ 0.1 |
CONSOLIDATED STATEMENTS OF CASH
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash flows from operating activities: | ||
Net income | $ 69 | $ 112 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation | 29 | 32 |
Amortization of intangible assets | 55 | 56 |
Deferred income taxes | (14) | (3) |
Stock based compensation expense | 11 | 13 |
Other non-cash expense | 2 | 16 |
Gain on sale of non-strategic businesses and product lines | 0 | (13) |
Changes in operating assets and liabilities, net of acquisitions: | ||
Accounts and notes receivable-trade, net | 34 | 13 |
Inventories, net | (41) | (51) |
Prepaid expenses and other current assets, net | (17) | (26) |
Other noncurrent assets | 3 | (13) |
Accounts payable | 19 | (16) |
Accrued liabilities | (53) | (79) |
Income taxes | 3 | (5) |
Other noncurrent liabilities | (7) | 13 |
Net cash provided by operating activities | 93 | 49 |
Cash flows from investing activities: | ||
Capital expenditures | (44) | (30) |
Cash paid for acquisitions of businesses and equity investments, net of cash acquired | 0 | (92) |
Cash received on sale of non-strategic businesses or product lines | 0 | 19 |
Cash received on derivative contracts | 1 | 0 |
Net cash used in investing activities | (43) | (103) |
Cash flows from financing activities: | ||
Cash paid for accelerated share repurchase | (150) | 0 |
Proceeds on short-term borrowings | 163 | 30 |
Cash paid for treasury stock | 0 | (90) |
Cash dividends paid | (24) | (22) |
Proceeds from long-term borrowings, net of deferred financing costs | 5 | 4 |
Repayments on long-term borrowings | (2) | 0 |
Proceeds from exercised stock options | 5 | 33 |
Other financing activities, net | (7) | (8) |
Net cash used in financing activities | (10) | (53) |
Effect of exchange rate changes on cash and cash equivalents | (5) | (13) |
Net increase (decrease) in cash and cash equivalents | 35 | (120) |
Cash and cash equivalents at beginning of period | 339 | 438 |
Cash and cash equivalents at end of period | $ 374 | $ 318 |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
SIGNIFICANT ACCOUNTING POLICIES | SIGNIFICANT ACCOUNTING POLICIES AND REVISION Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K for the year ended December 31, 2021, as amended and filed on November 7, 2022. Recently Concluded Investigation As previously disclosed, the Audit and Finance Committee of the Company’s Board of Directors (the “Audit and Finance Committee”), assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company. In the North America Investigation, the Audit and Finance Committee concluded that there was no evidence of intentional wrongdoing or fraud. The Audit and Finance Committee found that certain former members of senior management, including the Company’s former Chief Executive Officer and former Chief Financial Officer, violated provisions of the Company’s Code of Ethics and Business Conduct. In addition, these former members of senior management did not maintain and promote an appropriate control environment focused on compliance in areas of the Company’s business, nor did they sufficiently promote, monitor or enforce adherence to the Code of Ethics and Business Conduct. Based on the China Investigation, the Audit and Finance Committee concluded that members of the Company’s local commercial team in China, as well as the head of the Company’s Asia-Pacific commercial organization, committed intentional wrongdoing by failing to provide requested information to the Company’s local accounting team, by obstructing the work of the accounting team and by lacking truthfulness in providing information to the Company and to the Audit and Finance Committee as part of the China Investigation. The China Investigation also determined that these actions by the certain members of the Company’s local commercial team in China, as well as the former Chief Financial Officer and the head of the Company’s Asia-Pacific commercial organization, violated the Company’s Code of Ethics and Business Conduct. On October 29, 2022, the Audit and Finance Committee determined that its investigation was complete, and authorized the filing of these interim consolidated financial statements for the three-month period ended March 31, 2022. Correction of Previously Reported Interim Consolidated Quarterly Financial Statements The interim consolidated financial statements include immaterial corrections to the three-month period ended March 31, 2021 which were presented in Note 23 to the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 in the Company’s 2021 Form 10-K/A filed on November 7, 2022. This revision, which corrects for errors related to certain customer incentive programs as well as the accounting and assumptions in the determination of estimates related to the Company’s sales returns provisions, warranty reserve provisions and variable consideration, as well as other immaterial adjustments, results in a decrease to Net sales by $1 million, a decrease to Operating Income by $4 million and a decrease to Diluted EPS by $0.02 from amounts previously reported for the three-month period ended March 31, 2021. This revision did not result in a change to previously reported Gross Margin for the three-month period ended March 31, 2021. The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein, are substantially the same as presented in the Company’s 2021 Form 10-K/A filed on November 7, 2022, except as may be indicated below. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of Net sales and expense during the reporting period. Actual results could differ materially from those estimates. Specifically, for the three months ended March 31, 2022, some of these estimates and assumptions continue to be based on an ongoing evaluation of expected future impacts from the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly have a negative material impact on the Company’s financial condition, liquidity, or results of operations in future periods is highly uncertain and difficult to predict. More specifically, although demand for the Company’s products has largely recovered from the impact of rigorous preventive measures implemented at the outset of the pandemic, it continues to be affected by social distancing guidelines, dental practice safety protocols which reduce patient traffic, and some lingering patient reluctance to seek dental care. Also, impacts from the pandemic continue to be experienced in the form of more recent shortages and higher prices of raw materials such as electronic components, higher related transportation costs, and labor shortages. In the first quarter of 2022, the Company has experienced supply chain constraints, which has impacted its ability to timely produce and deliver certain products, and has also resulted in increases in shipping rates. To address these issues, the Company has taken steps to mitigate the impact of these trends, including continued emphasis on cost reduction and supply chain efficiencies. However, uncertainties remain regarding how long these impacts will continue, whether customer demand will fully return to pre-COVID-19 levels upon lifting of remaining government restrictions, or whether future variants of the virus may have an adverse impact on demand in affected markets. Accounting Pronouncements Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”, which was subsequently amended by ASU No. 2021-01 “Reference Rate Reform (Topic 848): Scope” in January 2021. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate (“LIBOR”) or another rate expected to be discontinued due to the reference rate reform. The amendments in this standard were effective upon issuance and generally can be applied to contract modifications made or evaluated through December 31, 2022. The Company does not expect this standard to have a material impact on its consolidated financial statements and related disclosures. In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (Topic 805), which requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value differs from the current approach. This standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures. |
REVENUE
REVENUE | 3 Months Ended |
Mar. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
REVENUE | REVENUE Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. Net sales disaggregated by product category for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended (in millions) 2022 2021 Equipment & Instruments $ 166 $ 171 CAD/CAM 106 129 Orthodontics 68 68 Implants 155 153 Healthcare 70 74 Technology & Equipment segment net sales $ 565 $ 595 Endodontic & Restorative $ 293 $ 312 Other Consumables 111 119 Consumables segment sales $ 404 $ 431 Total net sales $ 969 $ 1,026 Net sales disaggregated by geographic region for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended (in millions) 2022 2021 United States $ 308 $ 347 Europe 411 417 Rest of World 250 262 Total net sales $ 969 $ 1,026 Contract Assets and Liabilities The Company normally does not have contract assets in the course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. The Company had $64 million and $68 million of deferred revenue recorded in Accrued liabilities in the Consolidated Balance Sheets at March 31, 2022 and December 31, 2021, respecti vely . Prior year deferred revenue of approximately $32 million was recognized in the current year. The Company expects to recognize significantly all of the remaining deferred revenue within the next twelve months. Allowance for Doubtful Accounts Accounts and notes receivables-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $11 million at March 31, 2022 and $13 million at December 31, 2021. For the three months ended March 31, 2022 and 2021, changes to the provision for doubtful accounts including write-offs of accounts receivable that were previously reserved were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations. |
STOCK COMPENSATION
STOCK COMPENSATION | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
STOCK COMPENSATION | STOCK COMPENSATION The amounts of stock compensation expense recorded in the Company’s Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended (in millions) 2022 2021 Cost of products sold $ 1 $ — Selling, general, and administrative expense 9 13 Research and development expense 1 — Total stock based compensation expense $ 11 $ 13 Related deferred income tax benefit $ 1 $ 2 |
COMPREHENSIVE INCOME (LOSS)
COMPREHENSIVE INCOME (LOSS) | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
COMPREHENSIVE INCOME (LOSS) | COMPREHENSIVE INCOME (LOSS) Changes in Accumulated other comprehensive income (loss) (“AOCI”), net of tax, by component for the three months ended March 31, 2022 and 2021 were as follows: (in millions) Foreign Currency Translation Gain (Loss) Gain (Loss) on Cash Flow Hedges Gain (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2021 $ (366) $ (16) $ (103) $ (107) $ (592) Other comprehensive (loss) income before reclassifications and tax impact (37) 3 9 — (25) Tax expense (11) — (1) — (12) Other comprehensive (loss) income, net of tax, before reclassifications (48) 3 8 — (37) Amounts reclassified from accumulated other comprehensive income, net of tax — (1) — 1 — Net (decrease) increase in other comprehensive loss (48) 2 8 1 (37) Balance, net of tax, at March 31, 2022 $ (414) $ (14) $ (95) $ (106) $ (629) (in millions) Foreign Currency Translation Gain (Loss) Gain (Loss) on Cash Flow Hedges Gain (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2020 $ (187) $ (25) $ (119) $ (133) $ (464) Other comprehensive (loss) income before reclassifications and tax impact (74) (6) 9 3 (68) Tax (expense) benefit (25) 2 (2) (1) (26) Other comprehensive (loss) income, net of tax, before reclassifications (99) (4) 7 2 (94) Amounts reclassified from accumulated other comprehensive income, net of tax — 2 — 2 4 Net (decrease) increase in other comprehensive income (99) (2) 7 4 (90) Balance, net of tax, at March 31, 2021 $ (286) $ (27) $ (112) $ (129) $ (554) At March 31, 2022 and December 31, 2021, the cumulative tax adjustments were $156 million and $168 million, respectively, primarily related to foreign currency translation adjustments. The cumulative foreign currency translation adjustments included translation losses of $313 million and $250 million at March 31, 2022 and December 31, 2021, respectively, and cumulative losses on loans designated as hedges of net investments of $101 million and $116 million, respectively. These foreign currency translation losses were partially offset by movements on derivative financial instruments. Reclassifications out of AOCI to the Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 were insignificant. |
EARNINGS PER COMMON SHARE
EARNINGS PER COMMON SHARE | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
EARNINGS PER COMMON SHARE | EARNINGS PER COMMON SHARE The computation of basic and diluted earnings per common share for the three months ended March 31, 2022 and 2021 were as follows: Basic Earnings Per Common Share Three Months Ended (in millions, except per share amounts) 2022 2021 Net income attributable to Dentsply Sirona $ 69 $ 112 Weighted average common shares outstanding 217.0 218.8 Earnings per common share - basic $ 0.32 $ 0.51 Diluted Earnings Per Common Share Three Months Ended (in millions, except per share amounts) 2022 2021 Net income attributable to Dentsply Sirona $ 69 $ 112 Weighted average common shares outstanding 217.0 218.8 Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards 0.8 1.1 Total weighted average diluted shares outstanding 217.8 219.9 Earnings per common share - diluted $ 0.32 $ 0.51 For the three months ended March 31, 2022, the Company excluded from the computation of weighted average diluted shares outstanding 1.9 million of equivalent shares of common stock from stock options and RSUs because their effect would be antidilutive. For the three months ended March 31, 2021, the Company excluded 0.8 million of equivalent shares of common stock outstanding from stock options and RSUs because their effect would be antidilutive. The Board of Directors has approved a share repurchase program, up to $1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. At March 31, 2022, the Company had authorization to repurchase $770 million in shares of common stock remaining under the share repurchase program, which was further reduced by $30 million through final settlement of the accelerated share repurchase program in April 2022 as described below. On March 8, 2022, the Company entered into an Accelerated Share Repurchase Agreement (“ASR Agreement”) with a financial institution to purchase the Company’s common stock based on the volume-weighted average price of the Company’s common stock during the term of the agreement, less a discount. (in millions, except per share amounts) Initial Delivery Final Settlement Agreement Date Amount Paid Shares Received Price per share Value of Shares as a % of Contract Value Settlement Date Total Shares Received Average Price per Share March 8, 2022 $ 150 2.4 $ 50.44 80 % April 19, 2022 3.1 $ 48.22 The ASR agreement was accounted for as an initial delivery of common shares in a treasury stock transaction on March 9, 2022 of $120 million and a forward contract indexed to the Company’s common stock for an amount of common shares to be determined on the final settlement date. The forward contract met all applicable criteria for equity classification and was not accounted for as a derivative instrument. Therefore, the forward contract was recorded as Capital in excess of par value in the Consolidated Balance Sheets at March 31, 2022. The initial delivery of common stock reduced the weighted average common shares outstanding for both basic and diluted EPS. The forward contract did not impact the weighted average common shares outstanding for diluted EPS. |
BUSINESS COMBINATIONS
BUSINESS COMBINATIONS | 3 Months Ended |
Mar. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
BUSINESS COMBINATIONS | BUSINESS COMBINATIONS Acquisitions 2021 Transactions On July 1, 2021, the effective date of the transaction, the Company paid $7 million to acquire the remaining interest in the dental business of a partially owned affiliate based in Switzerland that primarily develops highly specialized software with a focus on CAD/CAM systems. The acquisition is expected to further accelerate the development of the Company’s specialized software related to CAD/CAM systems. The preliminary fair values of the assets acquired and liabilities assumed in connection with the acquisition of the affiliate included $4 million of Other current assets, $3 million of Intangible assets, $2 million of Current Liabilities and $1 million of Other long-term liabilities. The cash paid and the $4 million fair value of the previously-held interest in the entity prior to the acquisition has been allocated on the basis of the preliminary estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $7 million in goodwill. This goodwill is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company’s existing business operations, and is not deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the quarter ended March 31, 2022 were immaterial to the financial statements, resulting in an increase to goodwill of $2 million. Management is continuing to finalize its valuation of certain assets and liabilities including other intangible assets and will conclude its valuation no later than one year from the acquisition date. Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) In-process R&D $ 3 Indefinite On June 1, 2021, the effective date of the transaction, the Company paid $132 million to acquire substantially all of the assets of Propel Orthodontics LLC and certain of its affiliated entities, a privately-held business based in California (“Propel Orthodontics”). The acquired business manufactures and sells orthodontic devices and provides in-office and at-home orthodontic accessory devices to orthodontists and their patients primarily within the clear aligner market. The acquisition is expected to further accelerate the growth and profitability of the Company’s combined clear aligners business. The preliminary fair values of the assets acquired and liabilities assumed in connection with the Propel Orthodontics acquisition were as follows: (in millions) Other current assets $ 4 Intangible assets 66 Current liabilities (1) Net assets acquired 69 Goodwill 63 Purchase consideration $ 132 The purchase price has been allocated on the basis of the preliminary estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $63 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company’s existing business operations. The goodwill is expected to be deductible for tax purposes. Management is continuing to finalize its valuation of certain assets including other intangible assets and will conclude its valuation no later than one year from the acquisition date. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the quarter ended March 31, 2022 were immaterial to the financial statements, resulting in a reduction to goodwill of $2 million. Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 10 On January 21, 2021, the effective date of the transaction, the Company paid $94 million with the potential for additional earn-out provision payments of up to $10 million, to acquire 100% of the outstanding shares of Datum Dental, Ltd., a privately-held producer and distributor of specialized regenerative dental material based in Israel. The fair value of the earn-out provision has been valued at $9 million as of the transaction date, resulting in a total purchase price of $103 million. The fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows: (in millions) Cash and cash equivalents $ 2 Other current assets 2 Intangible assets 76 Current liabilities (2) Other long-term assets (liabilities), net (14) Net assets acquired 64 Goodwill 39 Purchase consideration $ 103 The purchase price has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $39 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company’s existing business operations. The goodwill is not deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the three months ended March 31, 2022 were immaterial to the financial statements, resulting in an increase to goodwill of $6 million. Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 15 In-process R&D 10 Indefinite Total $ 76 The results of operations for each of the acquired businesses above upon the effective date of each transaction have been included in the accompanying financial statements. These results, as well as the historical results for the above acquired businesses for the periods ended March 31, 2022 and March 31, 2021, are not material in relation to the Company’s net sales and earnings for those periods. The Company therefore does not believe these acquisitions represent material transactions either individually or in the aggregate requiring the supplemental pro-forma information prescribed by ASC 805 and accordingly, this information is not presented. Investment in Affiliates On June 4, 2021, the effective date of the transaction, the Company paid $16 million to acquire a minority interest in a U.K.-based, privately-held provider of healthcare consumables. The investment is recorded as an equity method investment within Other noncurrent assets in the Consolidated Balance Sheets. Divestitures On April 1, 2021, the Company disposed of certain orthodontics businesses based in Japan previously included as part of the Technologies & Equipment segment in exchange for a cash receipt of $8 million. The divestiture resulted in an immaterial loss recorded in Other expense (income), net in the Consolidated Statements of Operations for the year ended December 31, 2021. On February 1, 2021, the Company disposed of an investment casting business previously included as part of the Consumables segment in exchange for a cash receipt of $19 million. The divestiture resulted in a pre-tax gain of $13 million recorded in Other expense (income), net in the Consolidated Statements of Operations for the three months ended March 31, 2021. |
SEGMENT INFORMATION
SEGMENT INFORMATION | 3 Months Ended |
Mar. 31, 2022 | |
Segment Reporting [Abstract] | |
SEGMENT INFORMATION | SEGMENT INFORMATION The Company’s two operating segments are organized primarily by product and generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight. These operating segments are also the Company’s reportable segments in accordance with how the Company’s chief operating decision-maker regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources. The Company evaluates performance of the segments based on net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarters unallocated costs, restructuring and other costs, interest expense, net, other expense (income), net, amortization of intangible assets and depreciation resulting from the fair value step-up of property, plant, and equipment from acquisitions. A description of the products and services provided within each of the Company’s two reportable segments is provided below. Technologies & Equipment This segment is responsible for the design, manufacture, and sales of the Company’s dental technology and equipment products and healthcare products. These products include dental implants, CAD/CAM systems, orthodontic clear aligners, imaging systems, treatment centers, instruments, as well as medical devices. Consumables This segment is responsible for the design, manufacture, and sales of the Company’s consumable products which include various preventive, restorative, endodontic, and dental laboratory products. The Company’s segment information for the three months ended March 31, 2022 and 2021 was as follows: Net Sales Three Months Ended (in millions) 2022 2021 Technologies & Equipment $ 565 $ 595 Consumables 404 431 Total net sales $ 969 $ 1,026 Segment Adjusted Operating Income Three Months Ended (in millions) 2022 2021 Technologies & Equipment $ 86 $ 124 Consumables 135 149 Segment adjusted operating income 221 273 Reconciling items expense (income): All other (a) 65 63 Restructuring and other costs 3 3 Interest expense, net 12 14 Other expense (income), net (2) (9) Amortization of intangible assets 55 55 Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations 1 2 Income before income taxes $ 87 $ 145 (a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations. |
INVENTORIES
INVENTORIES | 3 Months Ended |
Mar. 31, 2022 | |
Inventory Disclosure [Abstract] | |
INVENTORIES | INVENTORIES Inventories, net were as follows: (in millions) March 31, 2022 December 31, 2021 Raw materials and supplies $ 142 $ 139 Work-in-process 78 72 Finished goods 333 304 Inventories, net $ 553 $ 515 The Company’s inventory reserve was $86 million at both March 31, 2022 and December 31, 2021. Inventories are stated at the lower of cost and net realizable value. |
RESTRUCTURING AND OTHER COSTS
RESTRUCTURING AND OTHER COSTS | 3 Months Ended |
Mar. 31, 2022 | |
Restructuring and Related Activities [Abstract] | |
RESTRUCTURING AND OTHER COSTS | RESTRUCTURING AND OTHER COSTS Restructuring and other costs for the three months ended March 31, 2022 and 2021 were immaterial to the Company’s Consolidated Statements of Operations as shown below: Affected Line Item in the Consolidated Statements of Operations Three Months Ended (in millions) 2022 2021 Cost of products sold $ — $ (2) Restructuring and other costs 3 3 Total restructuring and other costs $ 3 $ 1 The Company’s restructuring accruals at March 31, 2022 were as follows: Severance (in millions) 2020 and 2021 Plans 2022 Plans Total Balance at December 31, 2021 $ 5 $ 9 $ — $ 14 Provisions 1 — 1 2 Amounts applied (2) (2) — (4) Balance at March 31, 2022 $ 4 $ 7 $ 1 $ 12 Other Restructuring Costs (in millions) 2020 and 2021 Plans 2022 Plans Total Balance at December 31, 2021 $ 4 $ — $ — $ 4 Provisions — 1 — 1 Amounts applied — (1) — (1) Balance at March 31, 2022 $ 4 $ — $ — $ 4 The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows: (in millions) December 31, 2021 Provisions Amounts March 31, 2022 Technologies & Equipment $ 7 $ — $ (2) $ 5 Consumables 11 2 (3) 10 All Other — 1 — 1 Total $ 18 $ 3 $ (5) $ 16 The associated restructuring liabilities are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets. |
FINANCIAL INSTRUMENTS AND DERIV
FINANCIAL INSTRUMENTS AND DERIVATIVES | 3 Months Ended |
Mar. 31, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
FINANCIAL INSTRUMENTS AND DERIVATIVES | FINANCIAL INSTRUMENTS AND DERIVATIVES Derivative Instruments and Hedging Activities The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and cash flows. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes. The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at March 31, 2022 and the notional amounts expected to mature during the next 12 months. (in millions) Aggregate Notional Amount Aggregate Notional Amount Maturing within 12 Months Cash Flow Hedges Foreign exchange forward contracts $ 282 $ 215 Total derivative instruments designated as cash flow hedges $ 282 $ 215 Hedges of Net Investments Foreign exchange forward contracts $ 177 $ 89 Cross currency basis swaps 295 — Total derivative instruments designated as hedges of net investments $ 472 $ 89 Fair Value Hedges Interest rate swaps $ 250 $ — Foreign exchange forward contracts 204 77 Total derivative instruments designated as fair value hedges $ 454 $ 77 Derivative Instruments not Designated as Hedges Foreign exchange forward contracts $ 349 $ 349 Total derivative instruments not designated as hedges $ 349 $ 349 Cash Flow Hedges Foreign Exchange Risk Management The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows and the counterparties to the transactions are typically large international financial institutions. Interest Rate Risk Management The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. On May 26, 2020, the Company paid $31 million to settle the $150 million notional T-Lock contract, which partially hedged the interest rate risk of the $750 million senior unsecured notes. This loss is amortized over the ten-year life of the notes. As of March 31, 2022 and December 31, 2021, $24 million and $25 million, respectively, of this loss is remaining to be amortized from AOCI in future periods. AOCI Release Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At March 31, 2022, the Company expects to reclassify an immaterial amount of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 4, Comprehensive Income (Loss). Hedges of Net Investments in Foreign Operations The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of this exposure. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments and are included in AOCI. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows. The fair value of the foreign exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates, cross-currency swap basis rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects. On July 2, 2021, the Company entered into a cross currency basis swap totaling a notional amount of $300 million which matures on June 3, 2030. The cross currency basis swap is designated as a hedge of net investments. This contract effectively converts a portion of the $750 million bond coupon from 3.3% to 1.7%. On May 25, 2021, the Company re-established its euro net investment hedge portfolio by entering into eight foreign exchange forward contracts, each with a notional amount of 10 million euro. The original contracts have quarterly maturity dates through March 2023. The Company enters into additional foreign exchange contracts as individual contracts within the portfolio mature. As of March 31, 2022 the euro net investment hedge portfolio has an aggregate notional value of 160 million euro with maturity dates through March 2024. Fair Value Hedges Foreign Exchange Risk Management The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. On January 6, 2021 the Company entered into foreign exchange forward contracts with a notional value of SEK 1.3 billion as a result of an increase in intercompany loans denominated in Swedish kronor. The foreign exchange forwards are designated as fair value hedges. Interest Rate Risk Management On July 1, 2021, the Company entered into variable interest rate swaps with a notional amount of $250 million, which effectively converts a portion of the underlying fixed rate of 3.3% on the $750 million Senior Notes due June 2030 to a variable interest rate. Of the $250 million notional amount, $100 million has a term of five-years maturing on June 1, 2026 and $150 million has a term of nine years maturing on March 1, 2030. Derivative Instruments Not Designated as Hedges The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other expense (income), net in the Consolidated Statements of Operations. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in operating activities in the Consolidated Statements of Cash Flows. Gains and (losses) recorded in the Company’s Consolidated Statements of Operations related to the economic hedges not designated as hedges for the three months ended March 31, 2022 and 2021 were insignificant. Derivative Instrument Activity The amount of gains and losses recorded in the Company’s Consolidated Balance Sheets and Consolidated Statements of Operations related to all derivative instruments for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended March 31, 2022 (in millions) Gain (Loss) recognized in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ 3 Cost of products sold $ — $ — Interest rate swaps — Interest expense, net (1) — Total for cash flow hedging $ 3 $ (1) $ — Hedges of Net Investments Cross currency basis swaps $ 8 Interest expense, net $ — $ 1 Foreign exchange forward contracts 3 Other expense (income), net — — Total for net investment hedging $ 11 $ — $ 1 Fair Value Hedges Interest rate swaps $ — Interest expense, net $ — $ 1 Foreign exchange forward contracts (2) Other expense (income), net — 8 Total for fair value hedging $ (2) $ — $ 9 Three Months Ended March 31, 2021 (in millions) Gain (Loss) Recognized in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ (6) Cost of products sold $ (1) $ — Interest rate swaps — Interest expense, net (1) — Total for cash flow hedging $ (6) $ (2) $ — Hedges of Net Investments Cross currency basis swaps $ 9 Interest expense, net $ — $ 2 Total for net investment hedging $ 9 $ — $ 2 Fair Value Hedges Foreign exchange forward contracts $ — Interest expense, net $ — $ 16 Total for fair value hedging $ — $ — $ 16 Consolidated Balance Sheets Location of Derivative Fair Values The fair value and the location of the Company’s derivatives in the Consolidated Balance Sheets were as follows: March 31, 2022 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 23 $ 11 $ 2 $ 1 Interest rate swaps 2 — — 20 Cross currency basis swaps 3 1 — — Total $ 28 $ 12 $ 2 $ 21 Not Designated as Hedges: Foreign exchange forward contracts $ 3 $ — $ 4 $ — Total $ 3 $ — $ 4 $ — December 31, 2021 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 18 $ 11 $ 2 $ 1 Interest rate swaps 5 — — 9 Cross currency basis swaps 4 — — 7 Total $ 27 $ 11 $ 2 $ 17 Not Designated as Hedges: Foreign exchange forward contracts $ 1 $ — $ 1 $ — Total $ 1 $ — $ 1 $ — Balance Sheet Offsetting Substantially all of the Company’s derivative contracts are subject to netting arrangements; whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets. Offsetting of financial assets and liabilities under netting arrangements at March 31, 2022 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amount Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 37 $ — $ 37 $ (7) $ — $ 30 Cross currency basis swaps 4 — 4 (2) — 2 Total assets $ 41 $ — $ 41 $ (9) $ — $ 32 Liabilities Foreign exchange forward contracts $ 7 $ — $ 7 $ (7) $ — $ — Interest rate swaps 18 — 18 (2) — 16 Total liabilities $ 25 $ — $ 25 $ (9) $ — $ 16 Offsetting of financial assets and liabilities under netting arrangements at December 31, 2021 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amount Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 31 $ — $ 31 $ (9) $ — $ 22 Total assets $ 31 $ — $ 31 $ (9) $ — $ 22 Liabilities Foreign exchange forward contracts $ 4 $ — $ 4 $ (4) $ — $ — Interest rate swaps 4 — 4 (2) — 2 Cross currency basis swaps 4 — 4 (3) — 1 Total liabilities $ 12 $ — $ 12 $ (9) $ — $ 3 |
FAIR VALUE MEASUREMENT
FAIR VALUE MEASUREMENT | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
FAIR VALUE MEASUREMENT | FAIR VALUE MEASUREMENT The estimated fair value and carrying value of the Company’s total debt, including current portion, was $2,251 million and $2,219 million, respectively, at March 31, 2022. At December 31, 2021, the estimated fair value and carrying value were $2,239 million and $2,095 million, respectively. The fair value of long-term debt is based on recent trade information in the financial markets of the Company’s public debt or is determined by discounting future cash flows using interest rates available at March 31, 2022 and December 31, 2021 to companies with similar credit ratings for issues with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes. Assets and liabilities measured at fair value on a recurring basis The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows: March 31, 2022 (in millions) Total Level 1 Level 2 Level 3 Assets Interest rate swaps $ 2 $ — $ 2 $ — Cross currency basis swaps 4 — 4 — Foreign exchange forward contracts 37 — 37 — Long-term debt 18 — 18 — Total assets $ 61 $ — $ 61 $ — Liabilities Interest rate swaps $ 20 $ — $ 20 $ — Foreign exchange forward contracts 7 — 7 — Contingent considerations on acquisitions 9 — — 9 Total liabilities $ 36 $ — $ 27 $ 9 December 31, 2021 (in millions) Total Level 1 Level 2 Level 3 Assets Interest rate swaps $ 5 $ — $ 5 $ — Long term debt 4 — 4 — Cross currency basis swaps 4 — 4 — Foreign exchange forward contracts 30 — 30 — Total assets $ 43 $ — $ 43 $ — Liabilities Interest rate swaps $ 9 $ — $ 9 $ — Cross currency basis swaps 7 — 7 — Foreign exchange forward contracts 4 — 4 — Contingent considerations on acquisitions 10 — — 10 Total liabilities $ 30 $ — $ 20 $ 10 Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks. The Company utilizes interest rate swaps and foreign exchange forward contracts that are considered cash flow hedges. In addition, the Company at times employs certain cross currency interest rate swaps and forward exchange contracts that are considered hedges of net investment in foreign operations. There have been no transfers between levels during the three months ended March 31, 2022. |
INCOME TAXES
INCOME TAXES | 3 Months Ended |
Mar. 31, 2022 | |
Income Tax Disclosure [Abstract] | |
INCOME TAXES | INCOME TAXES Uncertainties in Income Taxes The Company recognizes the impact of a tax position in the interim consolidated financial statements if that position is more likely than not of being sustained on audit based on the technical merits of the position. Under ASC 740-10, the Company provides for uncertain tax positions and the related interest expense by adjusting unrecognized tax benefits and accrued interest accordingly. The Company recognizes potential interest and penalties related to unrecognized tax benefits in income tax expense. The Company files income tax returns in multiple jurisdictions based on its operations, some of which are under examination by taxing authorities. Certain amounts of unrecognized tax benefits may increase or decrease within twelve months of the reporting date of the Company’s consolidated financial statements, primarily due to the completion of ongoing income tax examinations. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next 12 months are not expected to be significant. Expiration of statutes of limitation in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $1 million. Of this approximately $1 million represents the amount of unrecognized tax benefits that, if recognized, would affect the effective income tax rate. Other Tax Matters The impact of discrete items is separately recognized in the quarter in which they occur. During the three months ended March 31, 2022, the Company recorded $1 million of tax expense for other discrete tax matters, none of which are individually significant. The decrease in the effective tax rate is due to the overall decrement in the Company’s performance and the corresponding earnings mix of jurisdictions in which Company does business. During the three months ended March 31, 2021, the Company recorded $1 million of tax benefit for other discrete tax matters. The Company also recorded a $4 million tax expense as a discrete item related to business divestitures. |
FINANCING ARRANGEMENTS
FINANCING ARRANGEMENTS | 3 Months Ended |
Mar. 31, 2022 | |
Debt Disclosure [Abstract] | |
FINANCING ARRANGEMENTS | FINANCING ARRANGEMENTS At March 31, 2022, the Company had $399 million of borrowing available under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company has a $500 million commercial paper program. The Company had $330 million and $170 million outstanding borrowings under the commercial paper facility at March 31, 2022 and December 31, 2021, respectively. The Company also has a $700 million multi-currency revolving credit facility which serves as a back-stop credit facility for the Company’s commercial paper program. At March 31, 2022 and December 31, 2021, there were no outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to $43 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings of $14 million. At March 31, 2022, the weighted-average interest rate for short-term debt was 1.2%. The Company’s revolving credit facility, term loans and senior notes contain certain affirmative and negative debt covenants relating to the Company’s operations and financial condition. At March 31, 2022, the Company was in compliance with all debt covenants. T he Company is required under certain of its debt agreements to deliver or make available to borrowers its unaudited financial statements on a timely basis each quarter along with the necessary certifications. As a result of the Company’s failure to file its unaudited financial statements for the fiscal quarters ended March 31, 2022 and June 30, 2022 by the reporting deadlines, the Company obtained the consents of the requisite lenders and noteholders of its outstanding indebtedness to extend the time period for delivery of such unaudited financial statements until November 14, 2022. Therefore, the Company has not suffered an event of default as a result of the delayed filings. |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
GOODWILL AND INTANGIBLE ASSETS | GOODWILL AND INTANGIBLE ASSETS The Company assesses both goodwill and indefinite-lived intangible assets for impairment annually as of April 1 or more frequently if events or changes in circumstances indicate the asset might be impaired. Based on the Company’s 2021 impairment test, it was determined that the fair values of its reporting units and indefinite-lived intangible assets more likely than not exceeded their respective carrying values, resulting in no impairment. The fair values of reporting units were computed using a discounted cash flow model with inputs developed using both internal and market-based data. Intangible assets were evaluated for impairment using an income approach, specifically a relief from royalty method, or using a qualitative assessment. A change in any of the estimates and assumptions used in the annual test, a decline in the overall markets or in the use of intangible assets among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. There can be no assurance that the Company’s future asset impairment testing will not result in a material charge to earnings. Subsequent to the annual impairment test, the Company considered qualitative and quantitative factors as of March 31, 2022 to determine whether any events or changes in circumstances had resulted in the likelihood that the goodwill or indefinite-lived intangible assets may have become more likely than not impaired during the course of the quarter, and concluded there were no such indicators. A reconciliation of changes in the Company’s goodwill by reportable segment were as follows: (in millions) Technologies & Equipment Consumables Total Balance at December 31, 2021 Goodwill $ 5,989 $ 880 $ 6,869 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,096 $ 880 $ 3,976 Translation and other (31) (1) (32) Balance at March 31, 2022 Goodwill $ 5,958 $ 879 $ 6,837 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,065 $ 879 $ 3,944 Identifiable definite-lived and indefinite-lived intangible assets were as follows: March 31, 2022 December 31, 2021 (in millions) Gross Accumulated Net Gross Accumulated Net Developed technology and patents $ 1,692 $ (777) $ 915 $ 1,729 $ (762) $ 967 Tradenames and trademarks 277 (90) 187 269 (79) 190 Licensing agreements 31 (26) 5 36 (32) 4 Customer relationships 1,090 (565) 525 1,091 (545) 546 Total definite-lived $ 3,090 $ (1,458) $ 1,632 $ 3,125 $ (1,418) $ 1,707 Indefinite-lived tradenames and trademarks $ 583 $ — $ 583 $ 598 $ — $ 598 In-process R&D (a) 13 — 13 14 — 14 Total indefinite-lived $ 596 $ — $ 596 $ 612 $ — $ 612 Total identifiable intangible assets $ 3,686 $ (1,458) $ 2,228 $ 3,737 $ (1,418) $ 2,319 (a) Intangible assets acquired in a business combination that are in-process and used in research and development (“R&D”) activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed. During the second quarter of 2021, the Company purchased certain developed technology rights for an initial payment of $3 million. The purchase consideration also includes minimum guaranteed contingent payments of $17 million to be made upon reaching certain regulatory and commercial milestones, which were not yet considered probable of payment as of March 31, 2022. |
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
COMMITMENTS AND CONTINGENCIES | COMMITMENTS AND CONTINGENCIES Contingencies On January 25, 2018, Futuredontics, Inc., a former wholly-owned subsidiary of the Company, received service of a purported class action lawsuit brought by Henry Olivares and other similarly situated individuals in the Superior Court of the State of California for the County of Los Angeles. In January 2019, an amended complaint was filed adding another named plaintiff, Rachael Clarke, and various claims. The plaintiff class alleges several violations of the California wage and hours laws, including, but not limited to, failure to provide rest and meal breaks and the failure to pay overtime. The parties have engaged in written and other discovery. On February 5, 2019, Plaintiff Calethia Holt (represented by the same counsel as Mr. Olivares and Ms. Clarke) filed a separate representative action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. On April 5, 2019, Plaintiff Kendra Cato filed a similar action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has agreed to resolve all three actions (Olivares, Holt, and Cato). The court in Cato approved the settlement in that case, the settlement payment has been made, and the court dismissed the lawsuit. The parties to Olivares and Holt are in the process of seeking court approval of that settlement. The expected settlement amount, which is immaterial to the financial statements, has been recorded as an accrued liability within the Company’s consolidated balance sheet as of March 31, 2022. On June 7, 2018, and August 9, 2018, two putative class action suits were filed, and later consolidated, in the Supreme Court of the State of New York, County of New York claiming that the Company and certain individual defendants, violated U.S. securities laws (the “State Court Action”) by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. (“Sirona”) with DENTSPLY International Inc. (the “Merger”). The amended complaint alleges that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products and that three distributors of the Company’s products had been engaging in anticompetitive conduct. The plaintiffs seek to recover damages on behalf of a class of former Sirona shareholders who exchanged their shares for shares of the Company’s stock in the Merger. On September 26, 2019, the Court granted the Company’s motion to dismiss all claims and a judgment dismissing the case was subsequently entered. On February 4, 2020, the Court denied plaintiffs’ post-judgment motion to vacate or modify the judgment and to grant them leave to amend their complaint. The plaintiffs appealed the dismissal and the denial of the post-judgment motion to the Supreme Court of the State of New York, Appellate Division, First Department, and the Company cross-appealed select rulings in the Court’s decision dismissing the action. The plaintiffs’ appeals and the Company’s cross-appeal were consolidated and argued on January 12, 2021. On February 2, 2021, the Appellate Division issued its decision upholding the dismissal of the State Court Action with prejudice on statute of limitations grounds. The Plaintiffs did not appeal the Appellate Division decision. On December 19, 2018, a related putative class action was filed in the U.S. District Court for the Eastern District of New York against the Company and certain individual defendants (the “Federal Class Action”). The plaintiff makes similar allegations and asserts the same claims as those asserted in the State Court Action. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between February 20, 2014, and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of (a) all purchasers of the Company’s stock during the period February 20, 2014 through August 7, 2018 and (b) former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company’s stock in the Merger. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021. Briefing on the motion to dismiss was fully submitted on May 21, 2021, and that motion is currently pending before the Court. On June 2, 2022, the Company was named as a defendant in a putative class action filed in the United States District Court for the Southern District of Ohio captioned City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. Casey, Jr. et al., No. 2:22-cv-02371 (S.D. Ohio), and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the United States District Court for the Southern District of New York captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the “Securities Litigation”). The complaints in the Securities Litigation are substantially similar and both allege that, during the period June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company’s former Chief Executive Officer, and Mr. Jorge Gomez, the Company’s former Chief Financial Officer, violated United States securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognizes revenue tied to distributor rebate and incentive programs. No specific amounts of damages have been alleged in these lawsuits. We will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. We intend to defend these lawsuits vigorously, but there can be no assurance that we will be successful in any defense. If any of the lawsuits are decided adversely, we may be liable for significant damages directly or under our indemnification obligations, which could adversely affect our business, results of operations and cash flows. At this stage, we are unable to assess whether any material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss. As a result of an audit by the IRS for fiscal years 2012 through 2013, on February 11, 2019, the IRS issued to the Company a “30-day letter” and a Revenue Agent’s Report (“RAR”), relating to the Company’s worthless stock deduction in 2013 in the amount of $546 million. The RAR disallows the deduction and, after adjusting the Company’s net operating loss carryforward, asserts that the Company is entitled to a refund of $5 million for 2012, has no tax liability for 2013, and owes a deficiency of $17 million in tax for 2014, excluding interest. In accordance with ASC 740, the Company recorded the tax benefit associated with the worthless stock deduction in the Company’s 2012 financial statements. In March 2019, the Company submitted a formal protest disputing on multiple grounds the proposed taxes. The Company and its advisors discussed its position with the IRS Appeals Office Team on October 28, 2020 and, on November 13, 2020, submitted a supplemental response to questions raised by the Appeals Team. The Company’s position continues to be reviewed by the IRS Appeals Office team. The Company believes the IRS’ position is without merit and believes that it is more likely-than-not the Company’s position will be sustained upon further review by the IRS Appeals Office Team. The Company has not accrued a liability relating to the proposed tax adjustments. However, the outcome of this dispute involves a number of uncertainties, including those inherent in the valuation of various assets at the time of the worthless stock deduction, and those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. If determined adversely, the dispute would result in a current period charge to earnings and could have a material adverse effect in the consolidated results of operations, financial position, and liquidity of the Company. The Swedish Tax Agency has disallowed certain of the Company’s interest expense deductions for the tax years from 2013 to 2018. If such interest expense deductions were disallowed, the Company would be subject to an additional $42 million in tax expense. The Company has appealed the disallowance to the Swedish Administrative Court. With respect to such deductions taken in the tax years from 2013 to 2014, the Court ruled against the Company on July 5, 2017. On August 7, 2017, the Company appealed the unfavorable decision of the Swedish Administrative Court. On November 5, 2018, the Company delivered its final argument to the Administrative Court of Appeals at a hearing. The European Union Commission has taken the view that Sweden’s interest deduction limitation rules are incompatible with European Union law and supporting legal opinions, and therefore the Company has not paid the tax or made provision in its financial statements for such potential expense. This view has now been confirmed by the European Union Court of Justice in a preliminary ruling requested by the Swedish Supreme Administrative Court. Subsequently, the Swedish Tax Authority has conceded in pending court proceedings that the Company should be granted further interest expense deductions, but still claims that interest expense deductions incurring a maximum additional tax expense of $11 million should be disallowed on grounds not relating to European Union law. The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters. In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Except as otherwise noted, the Company cannot predict what the eventual outcome of the above-described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity. While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses. Commitments Purchase Commitments The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At March 31, 2022, non-cancelable purchase commitments are as follows: (in millions) 2022 $ 119 2023 86 2024 35 2025 36 2026 43 Thereafter — Total $ 319 The above information should be read in conjunction with Part II, Item 7 “Contractual Obligations” and Part II, Item 8, Note 22 “Commitments and Contingencies” in our 2021 Form 10-K/A for the fiscal year ended December 31, 2021. Off-Balance Sheet Arrangements As of March 31, 2022, we had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above. Indemnification In the normal course of business to facilitate sale of our products and services, we indemnify certain parties: customers, vendors, lessors, and other parties with respect to certain matters, including, but not limited to, services to be provided by us and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and our executive officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim. It is not possible to make a reasonable estimate of the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material effect on our results of operations, cash flows or financial position. As of March 31, 2022, we did not have any material indemnification claims that were probable or reasonably possible. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period. |
SIGNIFICANT ACCOUNTING POLICI_2
SIGNIFICANT ACCOUNTING POLICIES (Policies) | 3 Months Ended |
Mar. 31, 2022 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K for the year ended December 31, 2021, as amended and filed on November 7, 2022. Recently Concluded Investigation As previously disclosed, the Audit and Finance Committee of the Company’s Board of Directors (the “Audit and Finance Committee”), assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company. In the North America Investigation, the Audit and Finance Committee concluded that there was no evidence of intentional wrongdoing or fraud. The Audit and Finance Committee found that certain former members of senior management, including the Company’s former Chief Executive Officer and former Chief Financial Officer, violated provisions of the Company’s Code of Ethics and Business Conduct. In addition, these former members of senior management did not maintain and promote an appropriate control environment focused on compliance in areas of the Company’s business, nor did they sufficiently promote, monitor or enforce adherence to the Code of Ethics and Business Conduct. Based on the China Investigation, the Audit and Finance Committee concluded that members of the Company’s local commercial team in China, as well as the head of the Company’s Asia-Pacific commercial organization, committed intentional wrongdoing by failing to provide requested information to the Company’s local accounting team, by obstructing the work of the accounting team and by lacking truthfulness in providing information to the Company and to the Audit and Finance Committee as part of the China Investigation. The China Investigation also determined that these actions by the certain members of the Company’s local commercial team in China, as well as the former Chief Financial Officer and the head of the Company’s Asia-Pacific commercial organization, violated the Company’s Code of Ethics and Business Conduct. On October 29, 2022, the Audit and Finance Committee determined that its investigation was complete, and authorized the filing of these interim consolidated financial statements for the three-month period ended March 31, 2022. Correction of Previously Reported Interim Consolidated Quarterly Financial Statements The interim consolidated financial statements include immaterial corrections to the three-month period ended March 31, 2021 which were presented in Note 23 to the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 in the Company’s 2021 Form 10-K/A filed on November 7, 2022. This revision, which corrects for errors related to certain customer incentive programs as well as the accounting and assumptions in the determination of estimates related to the Company’s sales returns provisions, warranty reserve provisions and variable consideration, as well as other immaterial adjustments, results in a decrease to Net sales by $1 million, a decrease to Operating Income by $4 million and a decrease to Diluted EPS by $0.02 from amounts previously reported for the three-month period ended March 31, 2021. This revision did not result in a change to previously reported Gross Margin for the three-month period ended March 31, 2021. The accounting policies of the Company, as applied in the interim consolidated financial statements presented herein, are substantially the same as presented in the Company’s 2021 Form 10-K/A filed on November 7, 2022, except as may be indicated below. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of Net sales and expense during the reporting period. Actual results could differ materially from those estimates. Specifically, for the three months ended March 31, 2022, some of these estimates and assumptions continue to be based on an ongoing evaluation of expected future impacts from the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly have a negative material impact on the Company’s financial condition, liquidity, or results of operations in future periods is highly uncertain and difficult to predict. More specifically, although demand for the Company’s products has largely recovered from the impact of rigorous preventive measures implemented at the outset of the pandemic, it continues to be affected by social distancing guidelines, dental practice safety protocols which reduce patient traffic, and some lingering patient reluctance to seek dental care. Also, impacts from the pandemic continue to be experienced in the form of more recent shortages and higher prices of raw materials such as electronic components, higher related transportation costs, and labor shortages. In the first quarter of 2022, the Company has experienced supply chain constraints, which has impacted its ability to timely produce and deliver certain products, and has also resulted in increases in shipping rates. To address these issues, the Company has taken steps to mitigate the impact of these trends, including continued emphasis on cost reduction and supply chain efficiencies. However, uncertainties remain regarding how long these impacts will continue, whether customer demand will fully return to pre-COVID-19 levels upon lifting of remaining government restrictions, or whether future variants of the virus may have an adverse impact on demand in affected markets. |
Revenue | Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services. |
Inventory | Inventories are stated at the lower of cost and net realizable value. |
Accounting Pronouncements Not Yet Adopted | Accounting Pronouncements Not Yet Adopted In March 2020, the FASB issued ASU No. 2020-04 “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting”, which was subsequently amended by ASU No. 2021-01 “Reference Rate Reform (Topic 848): Scope” in January 2021. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate (“LIBOR”) or another rate expected to be discontinued due to the reference rate reform. The amendments in this standard were effective upon issuance and generally can be applied to contract modifications made or evaluated through December 31, 2022. The Company does not expect this standard to have a material impact on its consolidated financial statements and related disclosures. In October 2021, the FASB issued ASU No. 2021-08, “Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers” (Topic 805), which requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value differs from the current approach. This standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures. |
Foreign Exchange Risk Management | Foreign Exchange Risk Management The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows and the counterparties to the transactions are typically large international financial institutions. |
Income Taxes | Under ASC 740-10, the Company provides for uncertain tax positions and the related interest expense by adjusting unrecognized tax benefits and accrued interest accordingly. The Company recognizes potential interest and penalties related to unrecognized tax benefits in income tax expense. |
Goodwill & Intangible Assets | The Company assesses both goodwill and indefinite-lived intangible assets for impairment annually as of April 1 or more frequently if events or changes in circumstances indicate the asset might be impaired. Based on the Company’s 2021 impairment test, it was determined that the fair values of its reporting units and indefinite-lived intangible assets more likely than not exceeded their respective carrying values, resulting in no impairment. The fair values of reporting units were computed using a discounted cash flow model with inputs developed using both internal and market-based data. Intangible assets were evaluated for impairment using an income approach, specifically a relief from royalty method, or using a qualitative assessment. A change in any of the estimates and assumptions used in the annual test, a decline in the overall markets or in the use of intangible assets among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. There can be no assurance that the Company’s future asset impairment testing will not result in a material charge to earnings. |
REVENUE (Tables)
REVENUE (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Revenue from Contract with Customer [Abstract] | |
Schedule of Disaggregation of Revenue | Net sales disaggregated by product category for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended (in millions) 2022 2021 Equipment & Instruments $ 166 $ 171 CAD/CAM 106 129 Orthodontics 68 68 Implants 155 153 Healthcare 70 74 Technology & Equipment segment net sales $ 565 $ 595 Endodontic & Restorative $ 293 $ 312 Other Consumables 111 119 Consumables segment sales $ 404 $ 431 Total net sales $ 969 $ 1,026 |
Revenue from External Customers by Geographic Areas | Net sales disaggregated by geographic region for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended (in millions) 2022 2021 United States $ 308 $ 347 Europe 411 417 Rest of World 250 262 Total net sales $ 969 $ 1,026 |
STOCK COMPENSATION (Tables)
STOCK COMPENSATION (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Share-based Payment Arrangement [Abstract] | |
Schedule of Stock Based Compensation | The amounts of stock compensation expense recorded in the Company’s Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended (in millions) 2022 2021 Cost of products sold $ 1 $ — Selling, general, and administrative expense 9 13 Research and development expense 1 — Total stock based compensation expense $ 11 $ 13 Related deferred income tax benefit $ 1 $ 2 |
COMPREHENSIVE INCOME (LOSS) (Ta
COMPREHENSIVE INCOME (LOSS) (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Equity [Abstract] | |
Schedule of Accumulated Other Comprehensive Income (Loss) | Changes in Accumulated other comprehensive income (loss) (“AOCI”), net of tax, by component for the three months ended March 31, 2022 and 2021 were as follows: (in millions) Foreign Currency Translation Gain (Loss) Gain (Loss) on Cash Flow Hedges Gain (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2021 $ (366) $ (16) $ (103) $ (107) $ (592) Other comprehensive (loss) income before reclassifications and tax impact (37) 3 9 — (25) Tax expense (11) — (1) — (12) Other comprehensive (loss) income, net of tax, before reclassifications (48) 3 8 — (37) Amounts reclassified from accumulated other comprehensive income, net of tax — (1) — 1 — Net (decrease) increase in other comprehensive loss (48) 2 8 1 (37) Balance, net of tax, at March 31, 2022 $ (414) $ (14) $ (95) $ (106) $ (629) (in millions) Foreign Currency Translation Gain (Loss) Gain (Loss) on Cash Flow Hedges Gain (Loss) on Net Investment and Fair Value Hedges Pension Liability Gain (Loss) Total Balance, net of tax, at December 31, 2020 $ (187) $ (25) $ (119) $ (133) $ (464) Other comprehensive (loss) income before reclassifications and tax impact (74) (6) 9 3 (68) Tax (expense) benefit (25) 2 (2) (1) (26) Other comprehensive (loss) income, net of tax, before reclassifications (99) (4) 7 2 (94) Amounts reclassified from accumulated other comprehensive income, net of tax — 2 — 2 4 Net (decrease) increase in other comprehensive income (99) (2) 7 4 (90) Balance, net of tax, at March 31, 2021 $ (286) $ (27) $ (112) $ (129) $ (554) |
EARNINGS PER COMMON SHARE (Tabl
EARNINGS PER COMMON SHARE (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Earnings Per Share [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted | The computation of basic and diluted earnings per common share for the three months ended March 31, 2022 and 2021 were as follows: Basic Earnings Per Common Share Three Months Ended (in millions, except per share amounts) 2022 2021 Net income attributable to Dentsply Sirona $ 69 $ 112 Weighted average common shares outstanding 217.0 218.8 Earnings per common share - basic $ 0.32 $ 0.51 Diluted Earnings Per Common Share Three Months Ended (in millions, except per share amounts) 2022 2021 Net income attributable to Dentsply Sirona $ 69 $ 112 Weighted average common shares outstanding 217.0 218.8 Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards 0.8 1.1 Total weighted average diluted shares outstanding 217.8 219.9 Earnings per common share - diluted $ 0.32 $ 0.51 |
Accelerated Share Repurchases | (in millions, except per share amounts) Initial Delivery Final Settlement Agreement Date Amount Paid Shares Received Price per share Value of Shares as a % of Contract Value Settlement Date Total Shares Received Average Price per Share March 8, 2022 $ 150 2.4 $ 50.44 80 % April 19, 2022 3.1 $ 48.22 |
BUSINESS COMBINATIONS (Tables)
BUSINESS COMBINATIONS (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Business Combination and Asset Acquisition [Abstract] | |
Schedule of Intangible Assets Acquired | Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) In-process R&D $ 3 Indefinite Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 10 Identifiable intangible assets acquired were as follows: Weighted Average Useful Life (in millions, except for useful life) Amount (in years) Developed technology $ 66 15 In-process R&D 10 Indefinite Total $ 76 |
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed | The preliminary fair values of the assets acquired and liabilities assumed in connection with the Propel Orthodontics acquisition were as follows: (in millions) Other current assets $ 4 Intangible assets 66 Current liabilities (1) Net assets acquired 69 Goodwill 63 Purchase consideration $ 132 The fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows: (in millions) Cash and cash equivalents $ 2 Other current assets 2 Intangible assets 76 Current liabilities (2) Other long-term assets (liabilities), net (14) Net assets acquired 64 Goodwill 39 Purchase consideration $ 103 |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Segment Reporting [Abstract] | |
Third Party Net Sales | The Company’s segment information for the three months ended March 31, 2022 and 2021 was as follows: Net Sales Three Months Ended (in millions) 2022 2021 Technologies & Equipment $ 565 $ 595 Consumables 404 431 Total net sales $ 969 $ 1,026 |
Segment Adjusted Operating Income | Segment Adjusted Operating Income Three Months Ended (in millions) 2022 2021 Technologies & Equipment $ 86 $ 124 Consumables 135 149 Segment adjusted operating income 221 273 Reconciling items expense (income): All other (a) 65 63 Restructuring and other costs 3 3 Interest expense, net 12 14 Other expense (income), net (2) (9) Amortization of intangible assets 55 55 Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations 1 2 Income before income taxes $ 87 $ 145 (a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations. |
INVENTORIES (Tables)
INVENTORIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Inventory Disclosure [Abstract] | |
Inventories, Net | Inventories, net were as follows: (in millions) March 31, 2022 December 31, 2021 Raw materials and supplies $ 142 $ 139 Work-in-process 78 72 Finished goods 333 304 Inventories, net $ 553 $ 515 |
RESTRUCTURING AND OTHER COSTS (
RESTRUCTURING AND OTHER COSTS (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Related Costs | Restructuring and other costs for the three months ended March 31, 2022 and 2021 were immaterial to the Company’s Consolidated Statements of Operations as shown below: Affected Line Item in the Consolidated Statements of Operations Three Months Ended (in millions) 2022 2021 Cost of products sold $ — $ (2) Restructuring and other costs 3 3 Total restructuring and other costs $ 3 $ 1 The Company’s restructuring accruals at March 31, 2022 were as follows: Severance (in millions) 2020 and 2021 Plans 2022 Plans Total Balance at December 31, 2021 $ 5 $ 9 $ — $ 14 Provisions 1 — 1 2 Amounts applied (2) (2) — (4) Balance at March 31, 2022 $ 4 $ 7 $ 1 $ 12 Other Restructuring Costs (in millions) 2020 and 2021 Plans 2022 Plans Total Balance at December 31, 2021 $ 4 $ — $ — $ 4 Provisions — 1 — 1 Amounts applied — (1) — (1) Balance at March 31, 2022 $ 4 $ — $ — $ 4 |
Cumulative Amounts for the Provisions and Adjustments and Amounts Applied for All the Plans by Segment | The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows: (in millions) December 31, 2021 Provisions Amounts March 31, 2022 Technologies & Equipment $ 7 $ — $ (2) $ 5 Consumables 11 2 (3) 10 All Other — 1 — 1 Total $ 18 $ 3 $ (5) $ 16 |
FINANCIAL INSTRUMENTS AND DER_2
FINANCIAL INSTRUMENTS AND DERIVATIVES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of Notional Amounts of Outstanding Derivative Positions | The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at March 31, 2022 and the notional amounts expected to mature during the next 12 months. (in millions) Aggregate Notional Amount Aggregate Notional Amount Maturing within 12 Months Cash Flow Hedges Foreign exchange forward contracts $ 282 $ 215 Total derivative instruments designated as cash flow hedges $ 282 $ 215 Hedges of Net Investments Foreign exchange forward contracts $ 177 $ 89 Cross currency basis swaps 295 — Total derivative instruments designated as hedges of net investments $ 472 $ 89 Fair Value Hedges Interest rate swaps $ 250 $ — Foreign exchange forward contracts 204 77 Total derivative instruments designated as fair value hedges $ 454 $ 77 Derivative Instruments not Designated as Hedges Foreign exchange forward contracts $ 349 $ 349 Total derivative instruments not designated as hedges $ 349 $ 349 |
Schedule of Derivative Instruments | The amount of gains and losses recorded in the Company’s Consolidated Balance Sheets and Consolidated Statements of Operations related to all derivative instruments for the three months ended March 31, 2022 and 2021 were as follows: Three Months Ended March 31, 2022 (in millions) Gain (Loss) recognized in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ 3 Cost of products sold $ — $ — Interest rate swaps — Interest expense, net (1) — Total for cash flow hedging $ 3 $ (1) $ — Hedges of Net Investments Cross currency basis swaps $ 8 Interest expense, net $ — $ 1 Foreign exchange forward contracts 3 Other expense (income), net — — Total for net investment hedging $ 11 $ — $ 1 Fair Value Hedges Interest rate swaps $ — Interest expense, net $ — $ 1 Foreign exchange forward contracts (2) Other expense (income), net — 8 Total for fair value hedging $ (2) $ — $ 9 Three Months Ended March 31, 2021 (in millions) Gain (Loss) Recognized in AOCI Consolidated Statements of Operations Location Effective Portion Reclassified from AOCI into Income (Expense) Recognized in Income (Expense) Cash Flow Hedges Foreign exchange forward contracts $ (6) Cost of products sold $ (1) $ — Interest rate swaps — Interest expense, net (1) — Total for cash flow hedging $ (6) $ (2) $ — Hedges of Net Investments Cross currency basis swaps $ 9 Interest expense, net $ — $ 2 Total for net investment hedging $ 9 $ — $ 2 Fair Value Hedges Foreign exchange forward contracts $ — Interest expense, net $ — $ 16 Total for fair value hedging $ — $ — $ 16 |
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value | The fair value and the location of the Company’s derivatives in the Consolidated Balance Sheets were as follows: March 31, 2022 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 23 $ 11 $ 2 $ 1 Interest rate swaps 2 — — 20 Cross currency basis swaps 3 1 — — Total $ 28 $ 12 $ 2 $ 21 Not Designated as Hedges: Foreign exchange forward contracts $ 3 $ — $ 4 $ — Total $ 3 $ — $ 4 $ — December 31, 2021 (in millions) Prepaid Expenses and Other Current Assets Other Noncurrent Assets Accrued Liabilities Other Noncurrent Liabilities Designated as Hedges: Foreign exchange forward contracts $ 18 $ 11 $ 2 $ 1 Interest rate swaps 5 — — 9 Cross currency basis swaps 4 — — 7 Total $ 27 $ 11 $ 2 $ 17 Not Designated as Hedges: Foreign exchange forward contracts $ 1 $ — $ 1 $ — Total $ 1 $ — $ 1 $ — |
Offsetting Derivative Assets and Liabilities | Offsetting of financial assets and liabilities under netting arrangements at March 31, 2022 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amount Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 37 $ — $ 37 $ (7) $ — $ 30 Cross currency basis swaps 4 — 4 (2) — 2 Total assets $ 41 $ — $ 41 $ (9) $ — $ 32 Liabilities Foreign exchange forward contracts $ 7 $ — $ 7 $ (7) $ — $ — Interest rate swaps 18 — 18 (2) — 16 Total liabilities $ 25 $ — $ 25 $ (9) $ — $ 16 Offsetting of financial assets and liabilities under netting arrangements at December 31, 2021 were as follows: Gross Amounts Not Offset in the Consolidated Balance Sheets (in millions) Gross Amounts Recognized Gross Amount Offset in the Consolidated Balance Sheets Net Amounts Presented in the Consolidated Balance Sheets Financial Instruments Cash Collateral Received/Pledged Net Amount Assets Foreign exchange forward contracts $ 31 $ — $ 31 $ (9) $ — $ 22 Total assets $ 31 $ — $ 31 $ (9) $ — $ 22 Liabilities Foreign exchange forward contracts $ 4 $ — $ 4 $ (4) $ — $ — Interest rate swaps 4 — 4 (2) — 2 Cross currency basis swaps 4 — 4 (3) — 1 Total liabilities $ 12 $ — $ 12 $ (9) $ — $ 3 |
FAIR VALUE MEASUREMENT (Tables)
FAIR VALUE MEASUREMENT (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Fair Value Disclosures [Abstract] | |
Schedule of assets and liabilities at fair value | The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows: March 31, 2022 (in millions) Total Level 1 Level 2 Level 3 Assets Interest rate swaps $ 2 $ — $ 2 $ — Cross currency basis swaps 4 — 4 — Foreign exchange forward contracts 37 — 37 — Long-term debt 18 — 18 — Total assets $ 61 $ — $ 61 $ — Liabilities Interest rate swaps $ 20 $ — $ 20 $ — Foreign exchange forward contracts 7 — 7 — Contingent considerations on acquisitions 9 — — 9 Total liabilities $ 36 $ — $ 27 $ 9 December 31, 2021 (in millions) Total Level 1 Level 2 Level 3 Assets Interest rate swaps $ 5 $ — $ 5 $ — Long term debt 4 — 4 — Cross currency basis swaps 4 — 4 — Foreign exchange forward contracts 30 — 30 — Total assets $ 43 $ — $ 43 $ — Liabilities Interest rate swaps $ 9 $ — $ 9 $ — Cross currency basis swaps 7 — 7 — Foreign exchange forward contracts 4 — 4 — Contingent considerations on acquisitions 10 — — 10 Total liabilities $ 30 $ — $ 20 $ 10 |
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | A reconciliation of changes in the Company’s goodwill by reportable segment were as follows: (in millions) Technologies & Equipment Consumables Total Balance at December 31, 2021 Goodwill $ 5,989 $ 880 $ 6,869 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,096 $ 880 $ 3,976 Translation and other (31) (1) (32) Balance at March 31, 2022 Goodwill $ 5,958 $ 879 $ 6,837 Accumulated impairment losses (2,893) — (2,893) Goodwill, net $ 3,065 $ 879 $ 3,944 |
Schedule of Definite-lived and Indefinite-lived Intangible Assets | Identifiable definite-lived and indefinite-lived intangible assets were as follows: March 31, 2022 December 31, 2021 (in millions) Gross Accumulated Net Gross Accumulated Net Developed technology and patents $ 1,692 $ (777) $ 915 $ 1,729 $ (762) $ 967 Tradenames and trademarks 277 (90) 187 269 (79) 190 Licensing agreements 31 (26) 5 36 (32) 4 Customer relationships 1,090 (565) 525 1,091 (545) 546 Total definite-lived $ 3,090 $ (1,458) $ 1,632 $ 3,125 $ (1,418) $ 1,707 Indefinite-lived tradenames and trademarks $ 583 $ — $ 583 $ 598 $ — $ 598 In-process R&D (a) 13 — 13 14 — 14 Total indefinite-lived $ 596 $ — $ 596 $ 612 $ — $ 612 Total identifiable intangible assets $ 3,686 $ (1,458) $ 2,228 $ 3,737 $ (1,418) $ 2,319 (a) Intangible assets acquired in a business combination that are in-process and used in research and development (“R&D”) activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed. |
COMMITMENTS AND CONTINGENCIES (
COMMITMENTS AND CONTINGENCIES (Tables) | 3 Months Ended |
Mar. 31, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Long-term Purchase Commitment | The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At March 31, 2022, non-cancelable purchase commitments are as follows: (in millions) 2022 $ 119 2023 86 2024 35 2025 36 2026 43 Thereafter — Total $ 319 |
SIGNIFICANT ACCOUNTING POLICI_3
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Net sales | $ (969) | $ (1,026) |
Net income | $ (69) | (112) |
Revision of Prior Period, Error Correction, Adjustment | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Net sales | $ 1 |
SIGNIFICANT ACCOUNTING POLICI_4
SIGNIFICANT ACCOUNTING POLICIES - Corrections to the Consolidated Statements Of Operations (Details) - USD ($) $ / shares in Units, $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Net sales | $ 969 | $ 1,026 |
Cost of products sold | 448 | 447 |
Gross profit | 521 | 579 |
Selling, general, and administrative expenses | 376 | 386 |
Research and development expenses | 45 | 40 |
Operating income (loss) | 97 | 150 |
Other expense (income), net | (2) | (9) |
Income (loss) before income taxes | 87 | 145 |
Provision for income taxes | 18 | 33 |
Net income | 69 | 112 |
Less: Net income attributable to noncontrolling interest | 0 | 0 |
Net income attributable to Dentsply Sirona | $ 69 | $ 112 |
Net income per common share attributable to Dentsply Sirona: | ||
Earnings per common share - basic (in dollars per share) | $ 0.32 | $ 0.51 |
Earnings per common share - diluted (in dollars per share) | $ 0.32 | $ 0.51 |
Revision of Prior Period, Error Correction, Adjustment | ||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Net sales | $ (1) |
SIGNIFICANT ACCOUNTING POLICI_5
SIGNIFICANT ACCOUNTING POLICIES - Corrections to the Consolidated Statements Of Comprehensive Income (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | ||
Net income | $ 69 | $ 112 |
Total comprehensive income | 32 | 22 |
Comprehensive income attributable to Dentsply Sirona | $ 32 | $ 22 |
REVENUE (Details)
REVENUE (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | |
Disaggregation of Revenue [Line Items] | |||
Net sales | $ 969 | $ 1,026 | |
Deferred revenue | 64 | $ 68 | |
Deferred revenue, revenue recognized | 32 | ||
Trade Accounts Receivable | |||
Disaggregation of Revenue [Line Items] | |||
Allowance for doubtful accounts and trade discounts | 11 | $ 13 | |
United States | Geographical Basis, Country of Sales | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 308 | 347 | |
Europe | Geographical Basis, Country of Sales | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 411 | 417 | |
Rest of World | Geographical Basis, Country of Sales | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 250 | 262 | |
Technology & Equipment segment net sales | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 565 | 595 | |
Technology & Equipment segment net sales | Equipment & Instruments | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 166 | 171 | |
Technology & Equipment segment net sales | CAD/CAM | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 106 | 129 | |
Technology & Equipment segment net sales | Orthodontics | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 68 | 68 | |
Technology & Equipment segment net sales | Implants | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 155 | 153 | |
Technology & Equipment segment net sales | Healthcare | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 70 | 74 | |
Consumables segment sales | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 404 | 431 | |
Consumables segment sales | Endodontic & Restorative | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | 293 | 312 | |
Consumables segment sales | Other Consumables | |||
Disaggregation of Revenue [Line Items] | |||
Net sales | $ 111 | $ 119 |
STOCK COMPENSATION (Details)
STOCK COMPENSATION (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock based compensation expense | $ 11 | $ 13 |
Related deferred income tax benefit | 1 | 2 |
Cost of products sold | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock based compensation expense | 1 | 0 |
Selling, general, and administrative expenses | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock based compensation expense | 9 | 13 |
Research and development expense | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Total stock based compensation expense | $ 1 | $ 0 |
COMPREHENSIVE INCOME (LOSS) - B
COMPREHENSIVE INCOME (LOSS) - BALANCES INCLUDED IN AOCI, NET OF TAX, IN THE CONSOLIDATED BALANCE SHEETS (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ||
Beginning Balance | $ 4,997 | $ 4,935 |
Net (decrease) increase in other comprehensive loss | (37) | (90) |
Ending Balance | 4,864 | 4,890 |
Accumulated Other Comprehensive Loss | ||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ||
Beginning Balance | (592) | (464) |
Other comprehensive (loss) income before reclassifications and tax impact | (25) | (68) |
Tax benefit (expense) | (12) | (26) |
Other comprehensive (loss) income, net of tax, before reclassifications | (37) | (94) |
Amounts reclassified from accumulated other comprehensive income, net of tax | 0 | 4 |
Net (decrease) increase in other comprehensive loss | (37) | (90) |
Ending Balance | (629) | (554) |
Foreign Currency Translation Gain (Loss) | ||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ||
Beginning Balance | (366) | (187) |
Other comprehensive (loss) income before reclassifications and tax impact | (37) | (74) |
Tax benefit (expense) | (11) | (25) |
Other comprehensive (loss) income, net of tax, before reclassifications | (48) | (99) |
Amounts reclassified from accumulated other comprehensive income, net of tax | 0 | 0 |
Net (decrease) increase in other comprehensive loss | (48) | (99) |
Ending Balance | (414) | (286) |
Gain (Loss) on Cash Flow Hedges | ||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ||
Beginning Balance | (16) | (25) |
Other comprehensive (loss) income before reclassifications and tax impact | 3 | (6) |
Tax benefit (expense) | 0 | 2 |
Other comprehensive (loss) income, net of tax, before reclassifications | 3 | (4) |
Amounts reclassified from accumulated other comprehensive income, net of tax | (1) | 2 |
Net (decrease) increase in other comprehensive loss | 2 | (2) |
Ending Balance | (14) | (27) |
Gain (Loss) on Net Investment and Fair Value Hedges | ||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ||
Beginning Balance | (103) | (119) |
Other comprehensive (loss) income before reclassifications and tax impact | 9 | 9 |
Tax benefit (expense) | (1) | (2) |
Other comprehensive (loss) income, net of tax, before reclassifications | 8 | 7 |
Amounts reclassified from accumulated other comprehensive income, net of tax | 0 | 0 |
Net (decrease) increase in other comprehensive loss | 8 | 7 |
Ending Balance | (95) | (112) |
Pension Liability Gain (Loss) | ||
Accumulated Other Comprehensive Income (Loss) [Roll Forward] | ||
Beginning Balance | (107) | (133) |
Other comprehensive (loss) income before reclassifications and tax impact | 0 | 3 |
Tax benefit (expense) | 0 | (1) |
Other comprehensive (loss) income, net of tax, before reclassifications | 0 | 2 |
Amounts reclassified from accumulated other comprehensive income, net of tax | 1 | 2 |
Net (decrease) increase in other comprehensive loss | 1 | 4 |
Ending Balance | $ (106) | $ (129) |
COMPREHENSIVE INCOME (LOSS) - A
COMPREHENSIVE INCOME (LOSS) - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 | Mar. 31, 2021 | Dec. 31, 2020 |
Derivative [Line Items] | ||||
Cumulative foreign currency translation adjustment gain (loss) | $ 4,864 | $ 4,997 | $ 4,890 | $ 4,935 |
Foreign Currency Translation Gain (Loss) | ||||
Derivative [Line Items] | ||||
Foreign currency tax adjustment | 156 | 168 | ||
Cumulative foreign currency translation adjustment gain (loss) | (414) | (366) | $ (286) | $ (187) |
Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest, Translation Gain (Loss) | ||||
Derivative [Line Items] | ||||
Cumulative foreign currency translation adjustment gain (loss) | (313) | (250) | ||
Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest, Net Investment Hedges | ||||
Derivative [Line Items] | ||||
Cumulative foreign currency translation adjustment gain (loss) | $ (101) | $ (116) |
EARNINGS PER COMMON SHARE - EAR
EARNINGS PER COMMON SHARE - EARNINGS PER SHARE COMPUTATION (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Basic Earnings Per Common Share | ||
Net income attributable to Dentsply Sirona | $ 69 | $ 112 |
Weighted average common shares outstanding (in shares) | 217 | 218.8 |
Earnings per common share - basic (in dollars per share) | $ 0.32 | $ 0.51 |
Diluted Earnings Per Common Share | ||
Net income attributable to Dentsply Sirona | $ 69 | $ 112 |
Weighted average common shares outstanding (in shares) | 217 | 218.8 |
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards (in shares) | 0.8 | 1.1 |
Total weighted average diluted shares outstanding (in shares) | 217.8 | 219.9 |
Earnings per common share - diluted (in dollars per share) | $ 0.32 | $ 0.51 |
EARNINGS PER COMMON SHARE - ADD
EARNINGS PER COMMON SHARE - ADDITIONAL INFORMATION (Details) - USD ($) shares in Millions, $ in Millions | 1 Months Ended | 3 Months Ended | |||
Apr. 30, 2022 | Mar. 31, 2022 | Mar. 31, 2021 | Mar. 09, 2022 | Jul. 28, 2021 | |
Accelerated Share Repurchases [Line Items] | |||||
Antidilutive common stock options not included in the computation of diluted earnings per common share (in shares) | 1.9 | 0.8 | |||
Stock repurchase program, authorized amount | $ 1,000 | ||||
Stock repurchase program, number of shares authorized to be repurchased | 770 | ||||
Accelerated share repurchase | $ (150) | ||||
Accelerated share repurchases, delivery of common shares | $ 120 | ||||
Subsequent Event | |||||
Accelerated Share Repurchases [Line Items] | |||||
Accelerated share repurchase | $ 30 |
EARNINGS PER COMMON SHARE - ACC
EARNINGS PER COMMON SHARE - ACCELERATED SHARE REPURCHASE PROGRAM (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions | Apr. 19, 2022 | Mar. 08, 2022 |
Accelerated Share Repurchases [Line Items] | ||
Amount Paid | $ 150 | |
Initial Delivery [Abstract] | ||
Shares received (in shares) | 2.4 | |
Price per share (in USD per share) | $ 50.44 | |
Value of Shares as a % of Contract Value | 80% | |
Subsequent Event | ||
Final Settlement [Abstract] | ||
Total Shares Received (in shares) | 3.1 | |
Average Price per Share (in usd per share) | $ 48.22 |
BUSINESS COMBINATIONS - ADDITIO
BUSINESS COMBINATIONS - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | 15 Months Ended | |||||||
Jul. 01, 2021 | Jun. 04, 2021 | Jun. 01, 2021 | Apr. 01, 2021 | Feb. 01, 2021 | Jan. 21, 2021 | Mar. 31, 2022 | Mar. 31, 2021 | Dec. 31, 2021 | Mar. 31, 2022 | |
Business Acquisition [Line Items] | ||||||||||
Goodwill | $ 3,944 | $ 3,976 | $ 3,944 | |||||||
Proceeds from divestiture of business | 0 | $ 19 | ||||||||
Gain on sale of business | 0 | $ 13 | ||||||||
UNITED KINGDOM | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Payments to acquire equity method investments | $ 16 | |||||||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Digital Dentistry Business | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Proceeds from divestiture of business | $ 8 | |||||||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Investment Casting Business | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Proceeds from divestiture of business | $ 19 | |||||||||
Gain on sale of business | 13 | |||||||||
Dental Business | SWITZERLAND | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Total acquisition consideration | $ 7 | |||||||||
Other current assets | 4 | |||||||||
Intangible assets | 3 | |||||||||
Current liabilities | 2 | |||||||||
Other long term liabilities | 1 | |||||||||
Fair value of the previously-held interest | 4 | |||||||||
Goodwill | $ 7 | |||||||||
Goodwill, period increase (decrease) | $ 2 | |||||||||
Propel Orthodontics | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Other current assets | $ 4 | |||||||||
Intangible assets | 66 | |||||||||
Current liabilities | 1 | |||||||||
Goodwill | 63 | |||||||||
Payments to acquire businesses, gross | $ 132 | |||||||||
Reduction in goodwill (less than) | $ 2 | |||||||||
Datum Dental, Ltd | ||||||||||
Business Acquisition [Line Items] | ||||||||||
Total acquisition consideration | $ 103 | |||||||||
Other current assets | 2 | |||||||||
Intangible assets | 76 | |||||||||
Current liabilities | 2 | |||||||||
Goodwill | 39 | |||||||||
Payments to acquire businesses, gross | 94 | |||||||||
Reduction in goodwill (less than) | $ (6) | |||||||||
Business combination, contingent consideration arrangements, range of outcomes, value, high | $ 10 | |||||||||
Percentage of voting interest acquired | 100% | |||||||||
Additional consideration based on earn out | $ 9 |
BUSINESS COMBINATIONS - FAIR VA
BUSINESS COMBINATIONS - FAIR VALUES OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 | Jun. 01, 2021 | Jan. 21, 2021 |
Business Acquisition [Line Items] | ||||
Goodwill | $ 3,944 | $ 3,976 | ||
Propel Orthodontics | ||||
Business Acquisition [Line Items] | ||||
Other current assets | $ 4 | |||
Intangible assets | 66 | |||
Current liabilities | (1) | |||
Net assets acquired | 69 | |||
Goodwill | 63 | |||
Purchase consideration | $ 132 | |||
Datum Dental, Ltd | ||||
Business Acquisition [Line Items] | ||||
Cash and cash equivalents | $ 2 | |||
Other current assets | 2 | |||
Intangible assets | 76 | |||
Current liabilities | (2) | |||
Other long-term assets (liabilities), net | (14) | |||
Net assets acquired | 64 | |||
Goodwill | 39 | |||
Purchase consideration | $ 103 |
BUSINESS COMBINATIONS - SUMMARY
BUSINESS COMBINATIONS - SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($) $ in Millions | Jul. 01, 2021 | Jun. 01, 2021 | Jan. 21, 2021 |
Propel Orthodontics | |||
Acquired Indefinite-lived Intangible Assets [Line Items] | |||
Intangible assets | $ 66 | ||
Datum Dental, Ltd | |||
Acquired Indefinite-lived Intangible Assets [Line Items] | |||
Intangible assets | $ 76 | ||
In-process R&D | |||
Acquired Indefinite-lived Intangible Assets [Line Items] | |||
Indefinite-lived intangible assets acquired, amount | $ 3 | ||
In-process R&D | Datum Dental, Ltd | |||
Acquired Indefinite-lived Intangible Assets [Line Items] | |||
Indefinite-lived intangible assets acquired, amount | 10 | ||
Developed technology | Propel Orthodontics | |||
Acquired Indefinite-lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets acquired, amount | $ 66 | ||
Weighted average useful life (in years) | 10 years | ||
Developed technology | Datum Dental, Ltd | |||
Acquired Indefinite-lived Intangible Assets [Line Items] | |||
Finite-lived intangible assets acquired, amount | $ 66 | ||
Weighted average useful life (in years) | 15 years |
SEGMENT INFORMATION - ADDITIONA
SEGMENT INFORMATION - ADDITIONAL INFORMATION (Details) | 3 Months Ended |
Mar. 31, 2022 segment | |
Segment Reporting [Abstract] | |
Number of operating groups | 2 |
SEGMENT INFORMATION - THIRD PAR
SEGMENT INFORMATION - THIRD PARTY NET SALES (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Revenue, Major Customer [Line Items] | ||
Net sales | $ 969 | $ 1,026 |
Technologies & Equipment | ||
Revenue, Major Customer [Line Items] | ||
Net sales | 565 | 595 |
Consumables | ||
Revenue, Major Customer [Line Items] | ||
Net sales | $ 404 | $ 431 |
SEGMENT INFORMATION - SEGMENT A
SEGMENT INFORMATION - SEGMENT ADJUSTED OPERATING INCOME (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Reconciling items expense (income): | ||
Segment adjusted operating income | $ 97 | $ 150 |
Other expense (income), net | (2) | (9) |
Amortization of intangible assets | 55 | 56 |
Income before income taxes | 87 | 145 |
Operating Segments | ||
Reconciling items expense (income): | ||
Segment adjusted operating income | 221 | 273 |
Operating Segments | Technologies & Equipment | ||
Reconciling items expense (income): | ||
Segment adjusted operating income | 86 | 124 |
Operating Segments | Consumables | ||
Reconciling items expense (income): | ||
Segment adjusted operating income | 135 | 149 |
All Other | ||
Reconciling items expense (income): | ||
All other | 65 | 63 |
Segment Reconciling Items | ||
Reconciling items expense (income): | ||
Restructuring and other costs | 3 | 3 |
Interest expense, net | 12 | 14 |
Other expense (income), net | (2) | (9) |
Amortization of intangible assets | 55 | 55 |
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations | $ 1 | $ 2 |
INVENTORIES - ADDITIONAL INFORM
INVENTORIES - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Inventory valuation reserve | $ 86 | $ 86 |
INVENTORIES - SUMMARY OF INVENT
INVENTORIES - SUMMARY OF INVENTORY (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Inventory Disclosure [Abstract] | ||
Raw materials and supplies | $ 142 | $ 139 |
Work-in-process | 78 | 72 |
Finished goods | 333 | 304 |
Inventories, net | $ 553 | $ 515 |
RESTRUCTURING AND OTHER COSTS -
RESTRUCTURING AND OTHER COSTS - CONSOLIDATED STATEMENTS OF OPERATIONS (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other costs | $ 3 | $ 1 |
Cost of products sold | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other costs | 0 | (2) |
Restructuring and other costs | ||
Restructuring Cost and Reserve [Line Items] | ||
Total restructuring and other costs | $ 3 | $ 3 |
RESTRUCTURING AND OTHER COSTS_2
RESTRUCTURING AND OTHER COSTS - RESTRUCTURING ACCURALS (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | $ 18 | |
Provisions | 3 | $ 3 |
Amounts applied | (5) | |
Ending Balance | 16 | |
Severance | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 14 | |
Provisions | 2 | |
Amounts applied | (4) | |
Ending Balance | 12 | |
Severance | 2020 and Prior Plans | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 5 | |
Provisions | 1 | |
Amounts applied | (2) | |
Ending Balance | 4 | |
Severance | 2021 Plans | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 9 | |
Provisions | 0 | |
Amounts applied | (2) | |
Ending Balance | 7 | |
Severance | 2022 Plans | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 0 | |
Provisions | 1 | |
Amounts applied | 0 | |
Ending Balance | 1 | |
Other Restructuring Costs | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 4 | |
Provisions | 1 | |
Amounts applied | (1) | |
Ending Balance | 4 | |
Other Restructuring Costs | 2020 and Prior Plans | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 4 | |
Provisions | 0 | |
Amounts applied | 0 | |
Ending Balance | 4 | |
Other Restructuring Costs | 2021 Plans | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 0 | |
Provisions | 1 | |
Amounts applied | (1) | |
Ending Balance | 0 | |
Other Restructuring Costs | 2022 Plans | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 0 | |
Provisions | 0 | |
Amounts applied | 0 | |
Ending Balance | $ 0 |
RESTRUCTURING AND OTHER COSTS_3
RESTRUCTURING AND OTHER COSTS - PROVISIONS AND ADJUSTMENTS AND AMOUNTS APPLIED FOR ALL PLANS BY SEGMENT (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | $ 18 | |
Provisions | 3 | $ 3 |
Amounts applied | (5) | |
Ending Balance | 16 | |
Operating Segments | Technologies & Equipment | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 7 | |
Provisions | 0 | |
Amounts applied | (2) | |
Ending Balance | 5 | |
Operating Segments | Consumables | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 11 | |
Provisions | 2 | |
Amounts applied | (3) | |
Ending Balance | 10 | |
All Other | ||
Restructuring Reserve [Roll Forward] | ||
Beginning Balance | 0 | |
Provisions | 1 | |
Amounts applied | 0 | |
Ending Balance | $ 1 |
FINANCIAL INSTRUMENTS AND DER_3
FINANCIAL INSTRUMENTS AND DERIVATIVES - SUMMARY OF DERIVATIVE INSTRUMENTS (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Jul. 01, 2021 |
Interest rate swaps | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | $ 250 | |
Derivative Instruments not Designated as Hedges | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | $ 349 | |
Aggregate Notional Amount Maturing within 12 Months | 349 | |
Derivative Instruments not Designated as Hedges | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 349 | |
Aggregate Notional Amount Maturing within 12 Months | 349 | |
Cash Flow Hedges | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 282 | |
Aggregate Notional Amount Maturing within 12 Months | 215 | |
Cash Flow Hedges | Designated as Hedging Instrument | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 282 | |
Aggregate Notional Amount Maturing within 12 Months | 215 | |
Hedges of Net Investments | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 472 | |
Aggregate Notional Amount Maturing within 12 Months | 89 | |
Hedges of Net Investments | Designated as Hedging Instrument | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 177 | |
Aggregate Notional Amount Maturing within 12 Months | 89 | |
Hedges of Net Investments | Designated as Hedging Instrument | Cross currency basis swaps | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 295 | |
Aggregate Notional Amount Maturing within 12 Months | 0 | |
Fair Value Hedges | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 454 | |
Aggregate Notional Amount Maturing within 12 Months | 77 | |
Fair Value Hedges | Designated as Hedging Instrument | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 204 | |
Aggregate Notional Amount Maturing within 12 Months | 77 | |
Fair Value Hedges | Designated as Hedging Instrument | Interest rate swaps | ||
Derivative [Line Items] | ||
Aggregate Notional Amount | 250 | |
Aggregate Notional Amount Maturing within 12 Months | $ 0 |
FINANCIAL INSTRUMENTS AND DER_4
FINANCIAL INSTRUMENTS AND DERIVATIVES - ADDITIONAL INFORMATION (Details) € in Millions, $ in Millions, kr in Billions | 3 Months Ended | 12 Months Ended | |||||||
Jul. 01, 2021 USD ($) | May 26, 2020 USD ($) | Mar. 31, 2022 USD ($) | Mar. 31, 2021 USD ($) | Dec. 31, 2021 USD ($) | Mar. 31, 2022 EUR (€) | Jul. 02, 2021 USD ($) | May 25, 2021 EUR (€) performancePeriod | Jan. 06, 2021 SEK (kr) | |
Derivative [Line Items] | |||||||||
Net gain on derivative financial instruments | $ 10 | $ 5 | |||||||
Senior Unsecured Notes Maturing June 1, 2030 | Senior Notes | |||||||||
Derivative [Line Items] | |||||||||
Debt instrument, face amount | $ 750 | $ 750 | |||||||
Debt instrument, interest rate, stated percentage | 3.30% | 1.70% | |||||||
Designated as Hedging Instrument | Hedges of Net Investments | |||||||||
Derivative [Line Items] | |||||||||
Derivative, notional amount | 472 | ||||||||
Gain (loss) in AOCI | (11) | (9) | |||||||
Designated as Hedging Instrument | Cash Flow Hedges | |||||||||
Derivative [Line Items] | |||||||||
Derivative, notional amount | 282 | ||||||||
Gain (loss) in AOCI | (3) | $ 6 | |||||||
Cross currency basis swaps | Designated as Hedging Instrument | Hedges of Net Investments | |||||||||
Derivative [Line Items] | |||||||||
Derivative, notional amount | $ 295 | ||||||||
Foreign exchange forward contracts | |||||||||
Derivative [Line Items] | |||||||||
Derivative, term of contract | 18 months | ||||||||
Derivative, notional amount | kr | kr 1.3 | ||||||||
Foreign exchange forward contracts | Designated as Hedging Instrument | Hedges of Net Investments | |||||||||
Derivative [Line Items] | |||||||||
Derivative, notional amount | € | € 160 | € 10 | |||||||
Foreign exchange forward contracts | performancePeriod | 8 | ||||||||
Interest rate swaps | |||||||||
Derivative [Line Items] | |||||||||
Derivative, notional amount | $ 250 | ||||||||
Interest Rate Swap Maturing June 1, 2026 | |||||||||
Derivative [Line Items] | |||||||||
Derivative, term of contract | 5 years | ||||||||
Derivative, notional amount | $ 100 | ||||||||
Interest Rate Swap Maturing March 1, 2030 | |||||||||
Derivative [Line Items] | |||||||||
Derivative, term of contract | 9 years | ||||||||
Derivative, notional amount | $ 150 | ||||||||
Cross Currency Interest Rate Contract | |||||||||
Derivative [Line Items] | |||||||||
Derivative, notional amount | $ 300 | ||||||||
Treasury Lock | Cash Flow Hedges | |||||||||
Derivative [Line Items] | |||||||||
Repayments of debt | 31 | ||||||||
Derivative, notional amount | $ 150 | ||||||||
Long-term debt, term | 10 years | ||||||||
Net gain on derivative financial instruments | $ 24 | $ 25 |
FINANCIAL INSTRUMENTS AND DER_5
FINANCIAL INSTRUMENTS AND DERIVATIVES - DERIVATIVE INSTRUMENTS - GAIN (LOSS) RECORDED IN AOCI IN THE CONSOLIDATED BALANCE SHEETS (Details) - Designated as Hedging Instrument - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | |
Cash Flow Hedges | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | $ 3 | $ (6) |
Effective Portion Reclassified from AOCI into Income (Expense) | (1) | (2) |
Recognized in Income (Expense) | 0 | 0 |
Cash Flow Hedges | Foreign exchange forward contracts | Cost of products sold | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | 3 | (6) |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | (1) |
Recognized in Income (Expense) | 0 | 0 |
Cash Flow Hedges | Interest rate swaps | Interest expense, net | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | 0 | 0 |
Effective Portion Reclassified from AOCI into Income (Expense) | (1) | (1) |
Recognized in Income (Expense) | 0 | 0 |
Hedges of Net Investments | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | 11 | 9 |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | 0 |
Recognized in Income (Expense) | 1 | 2 |
Hedges of Net Investments | Foreign exchange forward contracts | Other expense (income), net | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | 3 | |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | |
Recognized in Income (Expense) | 0 | |
Hedges of Net Investments | Cross currency basis swaps | Interest expense, net | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | 8 | 9 |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | 0 |
Recognized in Income (Expense) | 1 | 2 |
Fair Value Hedges | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | (2) | 0 |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | 0 |
Recognized in Income (Expense) | 9 | 16 |
Fair Value Hedges | Foreign exchange forward contracts | Interest expense, net | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | 0 | |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | |
Recognized in Income (Expense) | $ 16 | |
Fair Value Hedges | Foreign exchange forward contracts | Other expense (income), net | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | (2) | |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | |
Recognized in Income (Expense) | 8 | |
Fair Value Hedges | Interest rate swaps | Interest expense, net | ||
Derivative Instruments, Gain (Loss) [Line Items] | ||
Gain (Loss) recognized in AOCI | 0 | |
Effective Portion Reclassified from AOCI into Income (Expense) | 0 | |
Recognized in Income (Expense) | $ 1 |
FINANCIAL INSTRUMENTS AND DER_6
FINANCIAL INSTRUMENTS AND DERIVATIVES - BALANCE SHEET ALLOCATION (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | $ 41 | $ 31 |
Gross liability amount recognized for derivative instruments designated as hedges | 25 | 12 |
Interest rate swaps | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 18 | 4 |
Cross currency basis swaps | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 4 | |
Gross liability amount recognized for derivative instruments designated as hedges | 4 | |
Prepaid Expenses and Other Current Assets | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 28 | 27 |
Gross asset amount recognized for derivative instruments not designated as hedges | 3 | 1 |
Prepaid Expenses and Other Current Assets | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 23 | 18 |
Gross asset amount recognized for derivative instruments not designated as hedges | 3 | 1 |
Prepaid Expenses and Other Current Assets | Interest rate swaps | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 2 | 5 |
Prepaid Expenses and Other Current Assets | Cross currency basis swaps | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 3 | 4 |
Other Noncurrent Assets | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 12 | 11 |
Gross asset amount recognized for derivative instruments not designated as hedges | 0 | 0 |
Other Noncurrent Assets | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 11 | 11 |
Gross asset amount recognized for derivative instruments not designated as hedges | 0 | 0 |
Other Noncurrent Assets | Interest rate swaps | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 0 | 0 |
Other Noncurrent Assets | Cross currency basis swaps | ||
Derivative [Line Items] | ||
Gross asset amount recognized for derivative instruments designated as hedges | 1 | 0 |
Accrued Liabilities | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 2 | 2 |
Gross liability amount recognized for derivative instruments not designated as hedges | 4 | 1 |
Accrued Liabilities | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 2 | 2 |
Gross liability amount recognized for derivative instruments not designated as hedges | 4 | 1 |
Accrued Liabilities | Interest rate swaps | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 0 | 0 |
Accrued Liabilities | Cross currency basis swaps | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 0 | 0 |
Other Noncurrent Liabilities | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 21 | 17 |
Gross liability amount recognized for derivative instruments not designated as hedges | 0 | 0 |
Other Noncurrent Liabilities | Foreign exchange forward contracts | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 1 | 1 |
Gross liability amount recognized for derivative instruments not designated as hedges | 0 | 0 |
Other Noncurrent Liabilities | Interest rate swaps | Designated as Hedging Instrument | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | 20 | 9 |
Other Noncurrent Liabilities | Cross currency basis swaps | ||
Derivative [Line Items] | ||
Gross liability amount recognized for derivative instruments designated as hedges | $ 0 | $ 7 |
FINANCIAL INSTRUMENTS AND DER_7
FINANCIAL INSTRUMENTS AND DERIVATIVES - BALANCE SHEET OFFSETTING (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Assets | ||
Gross Amounts Recognized | $ 41 | $ 31 |
Gross Amount Offset in the Consolidated Balance Sheets | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheets | 41 | 31 |
Financial Instruments | (9) | (9) |
Cash Collateral Received/Pledged | 0 | 0 |
Net Amount | 32 | 22 |
Liabilities | ||
Gross Amounts Recognized | 25 | 12 |
Gross Amount Offset in the Consolidated Balance Sheets | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheets | 25 | 12 |
Financial Instruments | (9) | (9) |
Cash Collateral Received/Pledged | 0 | 0 |
Net Amount | 16 | 3 |
Foreign exchange forward contracts | ||
Assets | ||
Gross Amounts Recognized | 37 | 31 |
Gross Amount Offset in the Consolidated Balance Sheets | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheets | 37 | 31 |
Financial Instruments | (7) | (9) |
Cash Collateral Received/Pledged | 0 | 0 |
Net Amount | 30 | 22 |
Liabilities | ||
Gross Amounts Recognized | 7 | 4 |
Gross Amount Offset in the Consolidated Balance Sheets | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheets | 7 | 4 |
Financial Instruments | (7) | (4) |
Cash Collateral Received/Pledged | 0 | 0 |
Net Amount | 0 | 0 |
Interest rate swaps | ||
Liabilities | ||
Gross Amounts Recognized | 18 | 4 |
Gross Amount Offset in the Consolidated Balance Sheets | 0 | 0 |
Net Amounts Presented in the Consolidated Balance Sheets | 18 | 4 |
Financial Instruments | (2) | (2) |
Cash Collateral Received/Pledged | 0 | 0 |
Net Amount | 16 | 2 |
Cross currency basis swaps | ||
Assets | ||
Gross Amounts Recognized | 4 | |
Gross Amount Offset in the Consolidated Balance Sheets | 0 | |
Net Amounts Presented in the Consolidated Balance Sheets | 4 | |
Financial Instruments | (2) | |
Cash Collateral Received/Pledged | 0 | |
Net Amount | $ 2 | |
Liabilities | ||
Gross Amounts Recognized | 4 | |
Gross Amount Offset in the Consolidated Balance Sheets | 0 | |
Net Amounts Presented in the Consolidated Balance Sheets | 4 | |
Financial Instruments | (3) | |
Cash Collateral Received/Pledged | 0 | |
Net Amount | $ 1 |
FAIR VALUE MEASUREMENT - ADDITI
FAIR VALUE MEASUREMENT - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Estimate of Fair Value, Fair Value Disclosure | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Long-term debt | $ 2,251 | $ 2,239 |
Carrying (Reported) Amount, Fair Value Disclosure | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Long-term debt | $ 2,219 | $ 2,095 |
FAIR VALUE MEASUREMENT - ASSETS
FAIR VALUE MEASUREMENT - ASSETS AND LIABILITIES, RECURRING (Details) - Fair Value, Recurring - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | $ 61 | $ 43 |
Liabilities | 36 | 30 |
Interest rate swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 2 | 5 |
Liabilities | 20 | 9 |
Cross currency basis swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 4 | 4 |
Liabilities | 7 | |
Foreign exchange forward contracts | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 37 | 30 |
Liabilities | 7 | 4 |
Long-term debt | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 18 | 4 |
Contingent considerations on acquisitions | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Liabilities | 9 | 10 |
Level 1 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 0 | 0 |
Level 1 | Interest rate swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 0 | 0 |
Level 1 | Cross currency basis swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 0 | |
Level 1 | Foreign exchange forward contracts | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 0 | 0 |
Level 1 | Long-term debt | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Level 1 | Contingent considerations on acquisitions | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Liabilities | 0 | 0 |
Level 2 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 61 | 43 |
Liabilities | 27 | 20 |
Level 2 | Interest rate swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 2 | 5 |
Liabilities | 20 | 9 |
Level 2 | Cross currency basis swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 4 | 4 |
Liabilities | 7 | |
Level 2 | Foreign exchange forward contracts | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 37 | 30 |
Liabilities | 7 | 4 |
Level 2 | Long-term debt | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 18 | 4 |
Level 2 | Contingent considerations on acquisitions | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Liabilities | 0 | 0 |
Level 3 | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 9 | 10 |
Level 3 | Interest rate swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 0 | 0 |
Level 3 | Cross currency basis swaps | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 0 | |
Level 3 | Foreign exchange forward contracts | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Liabilities | 0 | 0 |
Level 3 | Long-term debt | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Assets | 0 | 0 |
Level 3 | Contingent considerations on acquisitions | ||
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||
Liabilities | $ 9 | $ 10 |
INCOME TAXES - ADDITIONAL INFOR
INCOME TAXES - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions | 3 Months Ended | 12 Months Ended | |
Mar. 31, 2022 | Mar. 31, 2021 | Mar. 31, 2023 | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Tax expense (benefit) for other discrete tax matters | $ (1) | $ 1 | |
Tax expense for business divestitures | $ 4 | ||
Forecast | |||
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |||
Unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations | $ 1 | ||
Unrecognized tax benefits that would impact effective tax rate | $ 1 |
FINANCING ARRANGEMENTS (Details
FINANCING ARRANGEMENTS (Details) - USD ($) | Mar. 31, 2022 | Dec. 31, 2021 |
Line of Credit Facility [Line Items] | ||
Borrowings available under lines of credit | $ 399,000,000 | |
Notes payable and current portion of long-term debt | $ 347,000,000 | $ 182,000,000 |
Debt, weighted average interest rate | 1.20% | |
Commercial paper | ||
Line of Credit Facility [Line Items] | ||
Notes payable and current portion of long-term debt | $ 330,000,000 | 170,000,000 |
Uncommitted Short-Term Financing | ||
Line of Credit Facility [Line Items] | ||
Notes payable and current portion of long-term debt | 43,000,000 | |
Other Short-term Loans | ||
Line of Credit Facility [Line Items] | ||
Notes payable and current portion of long-term debt | 14,000,000 | |
Line of Credit | Commercial paper | ||
Line of Credit Facility [Line Items] | ||
Maximum borrowing capacity | 500,000,000 | |
Line of Credit | Revolving Credit Facility | ||
Line of Credit Facility [Line Items] | ||
Maximum borrowing capacity | 700,000,000 | |
Notes payable and current portion of long-term debt | $ 0 | $ 0 |
GOODWILL AND INTANGIBLE ASSET_2
GOODWILL AND INTANGIBLE ASSETS - RECONCILIATION OF CHANGES IN GOODWILL (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2022 | Dec. 31, 2021 | |
Goodwill [Roll Forward] | ||
Goodwill | $ 6,837 | $ 6,869 |
Accumulated impairment losses | (2,893) | |
Goodwill, net, beginning of the year | 3,976 | |
Translation and other | (32) | |
Accumulated impairment losses | (2,893) | |
Goodwill, net, end of the year | 3,944 | |
Technologies & Equipment | ||
Goodwill [Roll Forward] | ||
Goodwill | 5,958 | 5,989 |
Accumulated impairment losses | (2,893) | |
Goodwill, net, beginning of the year | 3,096 | |
Translation and other | (31) | |
Accumulated impairment losses | (2,893) | |
Goodwill, net, end of the year | 3,065 | |
Consumables | ||
Goodwill [Roll Forward] | ||
Goodwill | 879 | $ 880 |
Accumulated impairment losses | 0 | |
Goodwill, net, beginning of the year | 880 | |
Translation and other | (1) | |
Accumulated impairment losses | 0 | |
Goodwill, net, end of the year | $ 879 |
GOODWILL AND INTANGIBLE ASSET_3
GOODWILL AND INTANGIBLE ASSETS - IDENTIFIABLE DEFINITE-LIVED AND INDEFINITE-LIVED INTANGIBLE ASSETS (Details) - USD ($) $ in Millions | Mar. 31, 2022 | Dec. 31, 2021 |
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite-lived tradenames and trademarks | $ 596 | $ 612 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 3,090 | 3,125 |
Accumulated Amortization | (1,458) | (1,418) |
Net Carrying Amount | 1,632 | 1,707 |
Total identifiable intangible assets, Gross Carrying Amount | 3,686 | 3,737 |
Identifiable intangible assets, net | 2,228 | 2,319 |
Tradenames and trademarks | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite-lived tradenames and trademarks | 583 | 598 |
In-process R&D | ||
Indefinite-lived Intangible Assets [Line Items] | ||
Indefinite-lived tradenames and trademarks | 13 | 14 |
Developed technology and patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 1,692 | 1,729 |
Accumulated Amortization | (777) | (762) |
Net Carrying Amount | 915 | 967 |
Tradenames and trademarks | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 277 | 269 |
Accumulated Amortization | (90) | (79) |
Net Carrying Amount | 187 | 190 |
Licensing agreements | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 31 | 36 |
Accumulated Amortization | (26) | (32) |
Net Carrying Amount | 5 | 4 |
Customer relationships | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Amount | 1,090 | 1,091 |
Accumulated Amortization | (565) | (545) |
Net Carrying Amount | $ 525 | $ 546 |
GOODWILL AND INTANGIBLE ASSET_4
GOODWILL AND INTANGIBLE ASSETS - NARRATIVE (Details) - Developed technology and patents - USD ($) $ in Millions | 3 Months Ended | |
Jun. 30, 2021 | Mar. 31, 2022 | |
Goodwill [Line Items] | ||
Payments to acquire intangible assets | $ 3 | |
Asset acquisition, contingent consideration, liability | $ 17 |
COMMITMENTS AND CONTINGENCIES -
COMMITMENTS AND CONTINGENCIES - ADDITIONAL INFORMATION (Details) | 2 Months Ended | 3 Months Ended | |
Nov. 05, 2018 USD ($) | Aug. 09, 2018 lawsuit | Mar. 31, 2022 USD ($) | |
Loss Contingencies [Line Items] | |||
Loss contingency, new claims filed, number | lawsuit | 2 | ||
Income tax effects allocated directly to equity, employee stock options | $ 546,000,000 | ||
IRS | Tax Year 2012 | |||
Loss Contingencies [Line Items] | |||
Liability (refund) from income tax examination | 5,000,000 | ||
IRS | Tax Year 2013 | |||
Loss Contingencies [Line Items] | |||
Liability (refund) from income tax examination | 0 | ||
IRS | Tax Year 2014 | |||
Loss Contingencies [Line Items] | |||
Income tax penalties | 17,000,000 | ||
Swedish Tax Agency | |||
Loss Contingencies [Line Items] | |||
Income tax examination, estimate of possible loss | $ 11,000,000 | $ 42,000,000 |
COMMITMENTS AND CONTINGENCIES_2
COMMITMENTS AND CONTINGENCIES - PURCHASE COMMITMENTS (Details) $ in Millions | Mar. 31, 2022 USD ($) |
Commitments and Contingencies Disclosure [Abstract] | |
2022 | $ 119 |
2023 | 86 |
2024 | 35 |
2025 | 36 |
2026 | 43 |
Thereafter | 0 |
Total | $ 319 |